[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 844
1. Schuster D, Klosterhalfen B, Fiedler C, Prescher A: [Metastasis of medullary plasmocytoma as the cause of acute cholecystitis]. Dtsch Med Wochenschr; 2007 Mar 23;132(12):612-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasis of medullary plasmocytoma as the cause of acute cholecystitis].
  • HISTORY AND ADMISSION FINDINGS: A 66-year-old man was found to have a medullary plasmocytoma the year before admission, after sustaining a pathological fracture of the femur.
  • INVESTIGATIONS: The clinical and sonographic findings and computed tomography suggested an acute cholecystitis.
  • Microscopic examination revealed metastatic infiltration of the gall bladder by a medullary plasmocytoma.
  • CONCLUSION: Secondary tumours of the gallbladder considered are thought to be rare.
  • The case discussed here is only the second one in which the metastatic tumor was a medullary plasmocytoma.
  • But a search for published and confirmed cases indicates that secondary tumors of the gall bladder are not so rare.
  • Metastatic tumors of the gall bladder should be kept in mind in the differential diagnosis of acute cholecystitis, especially in patients with an advanced primary tumor.
  • [MeSH-major] Brain Stem Neoplasms / complications. Cholecystitis, Acute / etiology. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / secondary. Plasmacytoma / complications. Plasmacytoma / secondary
  • [MeSH-minor] Aged. Cholecystectomy. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Cholecystitis.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357904.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


2. Goździuk K, Kedra M, Rybojad P, Sagan D: A rare case of solitary plasmacytoma mimicking a primary lung tumor. Ann Thorac Surg; 2009 Apr;87(4):e25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of solitary plasmacytoma mimicking a primary lung tumor.
  • Extramedullary plasmacytomas, especially located in the thorax, are very rare.
  • We present a 31-year-old patient who was diagnosed with a solitary plasmacytoma located in the lung mimicking a primary lung tumor.
  • After several weeks, this developed into multiple myeloma.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Multiple Myeloma / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324112.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


3. Schlamann M, Kollia K, Wanke I: [Plasmocytoma manifestation vs meningioma: diagnostic images and 1H magnetic resonance spectroscopy]]. Rofo; 2008 Jul;180(7):665-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasmocytoma manifestation vs meningioma: diagnostic images and 1H magnetic resonance spectroscopy]].
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy. Meningioma / diagnosis. Plasmacytoma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432561.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


Advertisement
4. Markou K, Karasmanis I, Goudakos JK, Papaioannou M, Psifidis A, Vital V: Extramedullary plasmacytoma of temporal bone: report of 2 cases and review of literature. Am J Otolaryngol; 2009 Sep-Oct;30(5):360-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary plasmacytoma of temporal bone: report of 2 cases and review of literature.
  • OBJECTIVE: The aim of the study was to report 2 cases of extramedullary plasmacytoma (EP) with localization to middle ear that were diagnosed and managed in our department.
  • Mild hearing loss and episodes of dizziness with sensation of falling for about 6 months were reported in the clinical history.
  • CONCLUSIONS: The prognosis of EP is considered favorable in regard to the solitary bone plasmacytoma and multiple myeloma (MM).
  • The differential diagnosis of EPs from other plasma cell dyscrasias and especially from MM is considered essential.
  • It is a radiosensitive tumor and, especially for EPs of temporal bone, the combined treatment of surgery resection and postoperative radiation seems to provide the best local control and the lower risk of occurrence.
  • [MeSH-major] Ear Neoplasms / pathology. Plasmacytoma / pathology. Temporal Bone / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720260.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


5. Sharma N, Sharma S, Bindra R: Plasmacytoma with amyloidosis masquerding as tuberculosis on cytology. J Cytol; 2009 Oct;26(4):161-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoma with amyloidosis masquerding as tuberculosis on cytology.
  • Fine needle aspiration cytology smears of the cervical lymph node were interpreted as tuberculous lymphadenitis based on the presence of an occasional epithelioid cell and caseous material.
  • Repeat aspiration from the lymph node showed numerous plasma cells and myeloma cells in addition to the amorphous material which was confirmed to be amyloid on staining with congo red.
  • A diagnosis of plasmacytoma with amyloidosis was rendered.
  • Imprint smears from nasal mass, detailed hematology workup and subsequent histology confirmed the diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Apr 15;59(8):1475-85 [3102035.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):60-4 [9556425.001]
  • [Cites] Radiology. 1991 Nov;181(2):521-5 [1924798.001]
  • [Cites] Acta Cytol. 2001 May-Jun;45(3):449-53 [11393084.001]
  • [Cites] Oral Oncol. 2006 Apr;42(4):421-9 [16488655.001]
  • [Cites] Ann Diagn Pathol. 2008 Feb;12(1):41-3 [18164414.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):287-91 [10833979.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):132-4 [11172308.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1513-7 [1540888.001]
  • (PMID = 21938185.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3168006
  • [Keywords] NOTNLM ; Plasmacytoma / amyloidosis / tuberculosis
  •  go-up   go-down


6. Cappuccio M, De Iure F, Gasbarrini A, Bandiera S, Boriani S: Solitary plasmacytoma of the spine: a 22 years follow-up case report. Eur Rev Med Pharmacol Sci; 2006 Sep-Oct;10(5):251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of the spine: a 22 years follow-up case report.
  • BACKGROUND AND OBJECTIVES: Plasmacytoma is a systemic malignancy and it is the most frequent primary tumor affecting the skeleton.
  • Progression from solitary plasmacytoma to systemic diffusion is reported to be 65-100% in 15 years.
  • A case report of a rare 22-year follow-up of a thoracic solitary plasmacytoma is here presented.
  • MATERIAL AND METHODS: Clinical case analysis, radiographs, magnetic resonance images and histological sections of the lesion are discussed.
  • Repeated surgical interventions were required due to progression and local recurrence of disease.
  • RESULTS: Although the inadequate surgical treatment, low response to chemotherapy and radiation therapy, and many local recurrences, no systemic diffusion of the disease was observed in 22 years.
  • [MeSH-major] Plasmacytoma / pathology. Spinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121318.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Gionanlis LC, Bamichas GI, Smias CV, Tzarou VN, Sombolos KI: Retroperitoneal plasmacytoma causing renal obstruction. Int Urol Nephrol; 2008;40(2):555-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal plasmacytoma causing renal obstruction.
  • [MeSH-major] Kidney Diseases / etiology. Plasmacytoma / complications
  • [MeSH-minor] Bone Neoplasms / pathology. Dilatation, Pathologic. Fatal Outcome. Humans. Male. Middle Aged. Paranasal Sinus Neoplasms / pathology. Retroperitoneal Space. Tomography, X-Ray Computed. Ureter / pathology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:373-6 [16304406.001]
  • [Cites] Int Urol Nephrol. 2007;39(3):929-33 [17549602.001]
  • [Cites] Hinyokika Kiyo. 1993 Jul;39(7):639-43 [8362683.001]
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):821-7 [16498114.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1228-9 [6692310.001]
  • [Cites] Intern Med J. 2005 Apr;35(4):211-5 [15836498.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):888 [12933502.001]
  • [Cites] Am J Hematol. 1998 Jul;58(3):235-8 [9662276.001]
  • [Cites] Indian J Cancer. 2004 Jul-Sep;41(3):133-4 [15472413.001]
  • [Cites] J Urol. 1992 Feb;147(2):452-4 [1732617.001]
  • (PMID = 18188673.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, Solano S, Pérez-Gracia JL, Oyajobi BO, Melero I: Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res; 2008 Nov 1;14(21):6895-906
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
  • PURPOSE: Eradication of post-treatment residual myeloma cells is needed to prevent relapses, and immunostimulatory monoclonal antibodies (mAb) such as anti-CD137, CTLA-4, CD40, etc., which enhance the immune response against malignancies, represent a means of achieving this purpose.
  • This study explores anti-CD137 mAbs for multiple myeloma treatment in preclinical models of the disease because they safely augment tumor immunity and are in clinical trials for other cancers.
  • EXPERIMENTAL DESIGN: The antitumor effect of anti-CD137 mAb on mouse plasmacytomas derived from HOPC and NS0 cell lines was studied and compared with that of anti-CTLA-4, anti-CD40, and anti-ICAM-2 mAbs.
  • The antitumor effect of anti-CD137 mAb was also examined in a mouse syngeneic disseminated myeloma (5TGM1) model, which more closely resembles human multiple myeloma.
  • Depletions of specific cell populations and gene-targeted mice were used to unravel the requirements for tumor rejection.
  • HOPC tumors, resulting in extended survival of mice that also became immune to rechallenge.
  • NS0-derived tumors that were dependent on IFN-gamma, natural killer cells, and CD8(+) T lymphocytes.
  • Natural killer cells accumulated in tumor draining lymph nodes and showed increased IFN-gamma production.
  • Importantly, anti-CD137 mAb treatment significantly decreased systemic tumor burden in the disseminated 5TGM1 model.
  • CONCLUSIONS: The immune-mediated antitumor activity of anti-CD137 mAb in mouse models holds promise for myeloma treatment in humans.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 2001 May 25;210(1):56-65 [11485353.001]
  • [Cites] Trends Immunol. 2005 Aug;26(8):440-6 [15979409.001]
  • [Cites] Nat Med. 2002 Apr;8(4):343-8 [11927939.001]
  • [Cites] J Immunol. 2002 Apr 15;168(8):3755-62 [11937526.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3167-74 [12036930.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4413-8 [12154048.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):1792-800 [12165501.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4230-6 [12370353.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):4882-8 [12391199.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1405-13 [12426559.001]
  • [Cites] Gene Ther. 2003 Jul;10(13):1067-78 [12808437.001]
  • [Cites] Eur J Immunol. 2003 Aug;33(8):2133-41 [12884287.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3546-54 [14506140.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5454-64 [14654524.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] Immunol Res. 2004;29(1-3):197-208 [15181282.001]
  • [Cites] Nat Med. 2004 Oct;10(10):1088-94 [15448685.001]
  • [Cites] Am J Pathol. 1988 Sep;132(3):593-7 [3414786.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):551-9 [8992967.001]
  • [Cites] Annu Rev Immunol. 1997;15:749-95 [9143706.001]
  • [Cites] Nat Med. 1997 Jun;3(6):682-5 [9176498.001]
  • [Cites] J Exp Med. 1997 Jul 7;186(1):47-55 [9206996.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Aug;5(5):357-63 [16101383.001]
  • [Cites] Cell Mol Immunol. 2004 Feb;1(1):31-6 [16212918.001]
  • [Cites] Int Immunol. 2006 Feb;18(2):325-33 [16373363.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2442-50 [16489051.001]
  • [Cites] Adv Immunol. 2006;90:297-339 [16730267.001]
  • [Cites] Nat Med. 2006 Jun;12(6):693-8 [16680149.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7276-84 [16849577.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73 [16925483.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):95-106 [17251916.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4194-213 [17371976.001]
  • [Cites] Oncologist. 2007 Mar;12(3):281-90 [17405892.001]
  • [Cites] Expert Opin Biol Ther. 2007 May;7(5):599-615 [17477799.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1150-7 [17344913.001]
  • [Cites] Int Rev Immunol. 2007 May-Aug;26(3-4):197-222 [17558744.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1701-8 [17541032.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):585-98 [17646864.001]
  • [Cites] Int J Cancer. 2007 Sep 15;121(6):1282-95 [17520674.001]
  • [Cites] Oncologist. 2007 Jul;12(7):873-83 [17673618.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):192-9 [17785201.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8891-9 [17875731.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):1116-21 [9541607.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5301-4 [9850053.001]
  • [Cites] Cell Immunol. 1998 Dec 15;190(2):167-72 [9878117.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1697-706 [10029599.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] J Clin Invest. 2002 Mar;109(5):651-9 [11877473.001]
  • (PMID = 18980984.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104180-04; United States / NCI NIH HHS / CA / K01 CA104180; United States / NCI NIH HHS / CA / K01 CA104180-05; United States / NCI NIH HHS / CA / KO1 CA104180; United States / NCI NIH HHS / CA / K01 CA104180-04; United States / NCI NIH HHS / CA / P30 CA054174
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD137; 0 / Antigens, CD40; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Ctla4 protein, mouse
  • [Other-IDs] NLM/ NIHMS77840; NLM/ PMC2583963
  •  go-up   go-down


9. Lewis K, Thomas R, Grace R, Moffat C, Manjaly G, Howlett DC: Extramedullary plasmacytomas of the larynx and parapharyngeal space: imaging and pathologic features. Ear Nose Throat J; 2007 Sep;86(9):567-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary plasmacytomas of the larynx and parapharyngeal space: imaging and pathologic features.
  • Extramedullary plasmacytoma is a rare plasma cell neoplasm that can occur in the head and neck.
  • In this article we describe a case of multiple synchronous extramedullary plasmacytomas involving the upper airway, pharynx, and larynx.
  • The clinical, imaging, and pathologic features of this neoplasm are discussed, together with potential treatment options.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Nasopharyngeal Diseases / diagnosis. Pharyngeal Neoplasms / diagnosis. Plasmacytoma / diagnosis

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970149.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Seegmiller AC, Xu Y, McKenna RW, Karandikar NJ: Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol; 2007 Feb;127(2):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma.
  • In such cases, it may be difficult to differentiate these lymphoma from plasmacytoma or myeloma, especially with limited diagnostic material.
  • However, there may be immunophenotypic differences in the plasma cells in these disorders that distinguish them.
  • This study characterizes the immunophenotypes of neoplastic plasma cells in 41 cases of B-lineage non-Hodgkin lymphoma and compares them with those in plasma cell myeloma.
  • We found that plasma cells in lymphoma were significantly more likely to express CD19, CD45, and surface immunoglobulin and less likely to express CD56 than those in myeloma.
  • Myeloma-associated osseous lesions and solitary plasmacytoma of bone showed myeloma-like immunophenotypes.
  • However, some extramedullary plasmacytomas showed lymphoma-like phenotypes, suggesting that, in reality, they may represent non-Hodgkin lymphomas with extensive plasmacytic differentiation.
  • [MeSH-major] Antigens, CD38 / analysis. Immunophenotyping / methods. Lymphoma, B-Cell / immunology. Multiple Myeloma / immunology
  • [MeSH-minor] Antigens, CD19 / analysis. Antigens, CD56 / analysis. Biopsy, Fine-Needle. Bone Neoplasms / immunology. Cell Differentiation. Flow Cytometry. Humans. Plasmacytoma / immunology. Thyroid Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2007 Feb;127(2):172-4 [17210527.001]
  • (PMID = 17210522.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD56; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


11. Lipsker D, Boeckler P: [Cutaneous manifestations of paraproteinemia and their mechanisms]. Presse Med; 2007 Jul-Aug;36(7-8):1135-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disease entities characterized by the presence of paraproteins have a variety of cutaneous manifestations.
  • These manifestations may be classified in the following categories as a function of their mechanisms: * extracutaneous deposition of paraproteins, as in amyloidosis * intravascular paraprotein deposition, as in cryoglobulinemia * cutaneous lesions resulting from the biologic activity of paraprotein, as in patients with normolipemic xanthoma with monoclonal immunoglobulin anti-LDL activity * abnormal cytokine secretion, as in AESOP (adenopathy and extensive skin patch overlying a plasmacytoma) or POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndromes * unknown mechanisms.
  • [MeSH-major] Paraproteinemias / complications. Paraproteinemias / diagnosis. Skin Diseases / etiology
  • [MeSH-minor] Amyloidosis / etiology. Blood Protein Electrophoresis. Cryoglobulinemia / etiology. Cytokines / physiology. Diagnosis, Differential. Humans. Immunoelectrophoresis. Immunoglobulins / physiology. POEMS Syndrome / etiology. Patient Selection. Purpura / etiology. Risk Factors. Schnitzler Syndrome / etiology. Urticaria / etiology. Vasculitis / etiology. Xanthomatosis / etiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289338.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunoglobulins
  • [Number-of-references] 19
  •  go-up   go-down


12. Jánosi J, Sebestyén A, Mikala G, Petö M, Jákó J, Domján G, Németh J, Kis Z, Kopper L, Vályi-Nagy I: [Soluble syndecan-1 levels in different plasma cell dyscrasias]. Orv Hetil; 2005 Jan 23;146(4):165-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soluble syndecan-1 levels in different plasma cell dyscrasias].
  • INTRODUCTION: Syndecans are a family of cell surface proteoglycans.
  • In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells.
  • The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias.
  • RESULTS: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance.
  • Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma.
  • In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted.
  • CONCLUSION: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis.
  • [MeSH-major] Membrane Glycoproteins / blood. Multiple Myeloma / blood. Paraproteinemias / blood. Plasmacytoma / blood. Proteoglycans / blood

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751511.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


13. Jagadeesan J, Oudit D, Hardwicke J, Shariff Z, McCoubrey G, Roberts G, Howcroft A: Solitary plasmocytoma of frontal bone presenting as an asymptomatic forehead lump. Dermatol Online J; 2006;12(3):24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmocytoma of frontal bone presenting as an asymptomatic forehead lump.
  • Solitary plasmocytoma of bone is a rare type of plasma cell tumor.
  • We present a case of a solitary extramedullary plasmacytoma of the frontal bone presenting as an asymptomatic forehead lump with clinically benign characteristics.
  • [MeSH-major] Frontal Bone. Plasmacytoma / pathology. Skull Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638438.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


14. Mielke F, Schweigert M: Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma. Nat Clin Pract Rheumatol; 2008 Apr;4(4):218-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma.
  • BACKGROUND: We report on a patient with rheumatoid arthritis (RA) who was treated with adalimumab and retrospectively diagnosed as having a multiple myeloma.
  • INVESTIGATIONS: In addition to the determination of clinical symptoms, investigations included radiography of the thorax, spine, hands and feet, arthrosonography, determination of laboratory parameters (including C-reactive protein levels and presence of antibodies against cyclic citrullinated peptide), cytogenetics and electrocardiography.
  • DIAGNOSIS: RA was initially diagnosed in 1988.
  • Plasmocytoma was diagnosed in 2004; however, investigation of medical records revealed evidence of multiple myeloma 8 years earlier, in 1996.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Multiple Myeloma / complications

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301411.001).
  • [ISSN] 1745-8390
  • [Journal-full-title] Nature clinical practice. Rheumatology
  • [ISO-abbreviation] Nat Clin Pract Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Pyridines; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; 202409-33-4 / etoricoxib; FYS6T7F842 / Adalimumab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Kitamura A, Yamashita Y, Hasegawa Y, Kojima H, Nagasawa T, Mori N: Primary lymphoma arising in the nasal cavity among Japanese. Histopathology; 2005 Nov;47(5):523-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Most lymphomas arising in the nasal cavity are thought to be of natural killer (NK) cell origin.
  • However, some reports indicate that T- and B-cell lymphomas may also primarily arise in the nasal cavity.
  • We diagnosed 31 cases as extranodal NK/T-cell lymphoma and one as plasmacytoma.
  • These immunohistochemical findings indicate their NK cell origin.
  • In one of these cases, neoplastic cells were positive for CD8beta and Valpha24, suggesting their NKT-cell origin.
  • CONCLUSIONS: Our present study indicates that primary lymphomas arising in the nasal cavity are mostly of NK cell derivation.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16242001.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Lobato JV, Maurício AC, Rodrigues JM, Cavaleiro MV, Cortez PP, Xavier L, Botelho C, Hussain NS, Santos JD: Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate. J Plast Reconstr Aesthet Surg; 2008;61(1):99-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
  • PURPOSE: Multiple myeloma, the second most common haematopoietic cancer, which represents the collection of plasma-cell neoplasms that invariably becomes fatal when self-renewing myeloma cells begin unrestrained proliferation.
  • The major clinical manifestation of multiple myeloma is related to the loss of bone through osteolysis.
  • Bisphosphonates are specific inhibitors of osteoclastic activity, and are currently used to prevent bone complications and to treat malignant hypercalcaemia in patients with multiple myeloma, or bone metastases from breast and prostate cancers.
  • Hence, osteonecrosis of the mandible has been reported in three patients from Centro Hospitalar de Vila Nova de Gaia (CHVNG) with multiple myeloma treated for over 18-48 months with intravenous zoledronate, commonly prescribed for multiple myeloma therapy.
  • Although, this report alerts clinicians about the potential complication of bone necrosis in patients receiving bisphosphonate therapy, many questions remain concerning the underlying pathogenesis of this process.
  • PATIENTS AND METHODS: The medical and dental records of three patients with multiple myeloma, who were treated in CHVNG in the past 4 years, were reviewed.
  • These three patients presented exposed bone and osteonecrosis of the mandible, and shared one common clinical feature: all of them were treated with bisphosphonate zoledronate, administered intravenously for long periods.
  • RESULTS: After a routine dental extraction, these patients developed avascular osteonecrosis of the mandible and secondary bone infection with Actinomyces israelii (actinomycotic osteomyelitis), with no evidence of metastatic disease evaluated by biopsy.
  • In these three described clinical cases, surgical debridment without flap elevation, intensive antibiotherapy and the suspension of the zoledronate treatment allowed a partial recovery of the patients.
  • The purpose of this clinical report is to point out that patients suffering from multiple myeloma can develop bone osteonecrosis induced by treatment with bisphosphonates.
  • Research to determine the mechanism of this dental phenomenon is needed to fully validate and substantiate the possible link between bisphosphonate treatment of multiple myeloma or other cancer diseases and avascular osteonecrosis of the jaws.
  • [MeSH-major] Bone Density Conservation Agents / adverse effects. Diphosphonates / adverse effects. Imidazoles / adverse effects. Mandibular Diseases / chemically induced. Multiple Myeloma / drug therapy. Osteonecrosis / chemically induced

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068658.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


17. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM: HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis; 2006 Nov 1;43(9):1198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various reports indicate a much higher incidence of monoclonal gammopathy among human immunodeficiency virus (HIV)-infected patients and a significantly younger age at diagnosis.
  • We sought to describe the laboratory findings and clinical course of MGUS, including association with plasma cell disorders, other malignancies, and infections, in 25 HIV-infected patients with a detectable serum monoclonal protein.
  • METHODS: We reviewed the patients' demographic characteristics, stage of HIV infection, and clinical course.
  • Laboratory studies included determination of CD4(+) T lymphocyte cell counts, HIV type 1 loads, and quantitative immunoglobulin levels; serum and urine protein immunoelectrophoresis; and determination of serum viscosity indices.
  • Skeletal surveys and bone marrow biopsies were performed in selected cases.
  • After a mean follow-up duration of 21 months, 7 patients (28%) received a diagnosis of a malignancy (multiple myeloma, in 1 patient; non-Hodgkin lymphoma, in 1; Hodgkin lymphoma, in 1; Kaposi sarcoma, in 2; and plasmacytoma, in 2).
  • CONCLUSIONS: Patients in our study were characterized by the detection of a monoclonal protein at a younger age and the increased presence of other viral infections (infection with hepatitis B or C virus or Kaposi sarcoma herpesvirus) than is typically seen in an HIV-uninfected cohort.


18. Walter C, Grötz KA, Kunkel M, Al-Nawas B: Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer; 2007 Feb;15(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Prevalence of bisphosphonate-associated osteonecrosis of the jaws within the catchment area of a university hospital maxillofacial unit and to review the outcome of treatment.
  • All BOJ patients took bisphosphonates because of metastatic diseases of the bone (plasmocytoma, mamma carcinoma and prostate cancer) for up to 5 years.
  • The importance of this new disease is characterised by the growing number of patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Bone Density Conservation Agents / adverse effects. Female. Germany / epidemiology. Humans. Male. Mandible / pathology. Maxilla / pathology. Middle Aged. Prevalence. Retrospective Studies

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Acad Med Singapore. 2004 Jul;33(4 Suppl):48-9 [15389307.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(2):135-7 [11373877.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jun;55(6):540-4; discussion 545-6 [9191633.001]
  • [Cites] J Oral Pathol Med. 2006 Mar;35(3):155-60 [16454811.001]
  • [Cites] Curr Med Chem. 2003 Jan;10(2):173-80 [12570716.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1080-4 [12006522.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):535-42 [15667977.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3890-4 [9307266.001]
  • [Cites] Br Med J. 1899 Jul 29;2(2013):270-1 [20758614.001]
  • [Cites] Arzneimittelforschung. 1996 Aug;46(8):759-62 [9125274.001]
  • [Cites] Bone. 1996 Feb;18(2):75-85 [8833200.001]
  • [Cites] J Lipid Res. 1992 Nov;33(11):1657-63 [1464749.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4253-4 [14615459.001]
  • [Cites] J Prosthet Dent. 1988 Feb;59(2):194-201 [2963910.001]
  • [Cites] Drugs. 2004;64(11):1197-211 [15161327.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Breast Cancer Res. 2002;4(1):30-4 [11879557.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Jun;32(3):289-95 [12767877.001]
  • [Cites] J Bone Miner Res. 2004 Jan;19(1):147-54 [14753746.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Oct;61(10):1238-9 [14586868.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6538-44 [12438248.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Jan;53(1):71-80 [15607935.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 [12183663.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] J Natl Cancer Inst. 1992 May 20;84(10):788-92 [1573666.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):321-7 [12927572.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Jun;62(6):763-4 [15181903.001]
  • [Cites] Aust Dent J. 2003 Dec;48(4):268 [14738134.001]
  • [Cites] Dtsch Zahnarztl Z. 1986 Apr;41(4):440-3 [3461965.001]
  • [Cites] Breast. 2001 Oct;10(5):447-9 [14965623.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):7317-25 [15590626.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • (PMID = 16941133.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


19. Kotil K: Pathological fracture of the atlas secondary to plasmacytoma. J Clin Neurosci; 2007 May;14(5):492-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological fracture of the atlas secondary to plasmacytoma.
  • Plasmacytoma of the atlas with pathological fracture has not been previously reported.
  • Using a transcondylar approach, the tumor was removed, and posterolateral fixation and fusion (using iliac autograft) was performed.
  • Biopsy was reported as plasmacytoma.
  • Although the primary treatment of plasmacytoma is non-surgical, the need for tissue diagnosis in relevant areas may dictate an open biopsy procedure.
  • [MeSH-major] Fractures, Spontaneous. Plasmacytoma / pathology. Spinal Fractures

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346972.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


20. Alcaide-Matas F, Galán-Alvarez P, Campano-Cruz I, Fernández-Alonso A, Oliva-Berini E, García-Olives F: [Solitary extramedullary plasmocytoma in the perianal area]. Cir Esp; 2007 Jan;81(1):54-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary extramedullary plasmocytoma in the perianal area].
  • [Transliterated title] Plasmocitoma solitario extramedular de localización perianal.
  • [MeSH-major] Anus Neoplasms. Plasmacytoma

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263964.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


21. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadié M, Simonetti A, Lutz JM, Berrino F, HAEMACARE Working Group: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood; 2010 Nov 11;116(19):3724-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.
  • The commonest LMs were plasma cell neoplasms (4.62), small B-cell lymphocytic lymphoma/chronic lymphatic leukemia (3.79), diffuse B-cell lymphoma (3.13), and Hodgkin lymphoma (2.41).
  • The commonest MMs were acute myeloid leukemia (2.96), other myeloproliferative neoplasms (1.76), and myelodysplastic syndrome (1.24).
  • [MeSH-major] Hematologic Neoplasms / epidemiology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood. 2011 Mar 24;117(12):3477
  • (PMID = 20664057.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Hackl M; Hackl J; Maynadie M; Holleczek B; Tryggvadottir L; Comber H; Bellu F; Giacomin A; Ferretti S; Crocetti E; Serraino D; Vercelli M; Federico M; Fusco R; Michiara M; Tumino R; Mangone L; Falcini F; Iannelli A; Budroni M; Zanetti R; Piffer S; La Rosa F; Zambon P; Sant M; Allemani C; Berrino F; Sowe S; Tereanu C; Capocaccia R; De Angelis R; Simonetti A; England K; Langmark F; Rachtan J; Mezyk R; Zwierko M; Ondrusova M; Primic-Žakelj M; Marcos-Gragera R; Khan S; Jundt G; Usel M; Ess SM; Bordoni A; Visser O; Otter R; Coebergh JW; Siesling S; Greenberg D; Easey N; Roche M; Lawrence G; Gavin A; Brewster DH; Steward J
  •  go-up   go-down


22. Waton J, Fays-Michel S, Chandeclerc ML, Corby S, Cuny JF, Barbaud A, Schmutz JL: [AA amyloidosis: a little-known complication of chronic leg ulcer]. Ann Dermatol Venereol; 2008 Feb;135(2):119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Amylose AA: une complication méconnue des ulcères chroniques de jambes.
  • AL amyloidosis was suspected in both cases because of a history of monoclonal gammopathy in one patient and of plasmocytoma in the other.
  • The diagnosis of AA amyloidosis was confirmed on renal histology through the detection of AA antibodies in amyloid deposits.
  • [MeSH-minor] Aged. Chronic Disease. Humans. Immunoglobulin gamma-Chains / analysis. Immunoglobulin kappa-Chains / analysis. Immunoglobulin lambda-Chains / analysis. Male. Middle Aged. Monoclonal Gammopathy of Undetermined Significance / complications. Plasmacytoma / complications. Renal Insufficiency / etiology


23. Mellor PJ, Polton GA, Brearley M, Haugland S, Smith KC, Scase TJ, McNeil PE, Holloway A, Archer J, Powell RM, Villiers EJ, Herrtage ME, Argyle DJ, Day MJ: Solitary plasmacytoma of bone in two successfully treated cats. J Feline Med Surg; 2007 Feb;9(1):72-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone in two successfully treated cats.
  • This is the first report of feline solitary plasmacytoma of bone.
  • We describe the clinical, clinico-pathological, radiographic and pathological findings of two successfully treated cats with long-term follow-up.
  • A biopsy of L6 revealed neoplastic plasma cell infiltration.
  • Clinical signs resolved completely and 4 years after diagnosis the cat remains well and has no electrophoretically detectable paraproteinaemia.
  • A biopsy of sacral bone demonstrated neoplastic plasma cell infiltration.
  • The animal was normoglobulinaemic.
  • Cytological examination of a fine needle aspirate confirmed recurrence of plasma cell neoplasia.
  • Eighteen months into vincristine therapy, there was recurrence of clinical signs and the cat was euthanased, more than 6 years after the initial diagnosis.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / therapy. Plasmacytoma / veterinary. Spinal Neoplasms / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887373.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Fayyaz A, Ghani UF: Multiple breast masses in a case of multiple myeloma. J Coll Physicians Surg Pak; 2009 Aug;19(8):529-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple breast masses in a case of multiple myeloma.
  • Myeloma of the breast is a rare entity with only a few reported cases in the literature.
  • It is usually secondary to adjacent bone disease with only a few instances of primary involvement of the breast.
  • We present a rare case of plasmacytoma of left humerus that presented with multiple breast masses and skin nodules.
  • Histopathology of the breast and skin nodules showed plasma cells consistent with the diagnosis of multiple myeloma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Adult. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Fatal Outcome. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19651021.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


25. Suvannasankha A, Abonour R, Cummings OW, Liangpunsakul S: Gastrointestinal plasmacytoma presenting as gastrointestinal bleeding. Clin Lymphoma Myeloma; 2008 Oct;8(5):309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal plasmacytoma presenting as gastrointestinal bleeding.
  • Clinical manifestations of gastrointestinal (GI) involvement in multiple myeloma (MM) are uncommon.
  • We report a case of plasmacytoma presenting as upper GI bleeding in a patient with a known diagnosis of MM.
  • The aim of our report is to heighten the awareness of plasmacytoma as an etiology of GI bleeding in patients with MM.
  • [MeSH-major] Colon / pathology. Gastrointestinal Diseases / diagnosis. Gastrointestinal Diseases / physiopathology. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / physiopathology. Hemorrhage / diagnosis. Multiple Myeloma / physiopathology. Plasmacytoma / diagnosis. Plasmacytoma / physiopathology
  • [MeSH-minor] Anemia. Diagnosis, Differential. Humans. Male. Melena. Middle Aged. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / physiopathology. Time Factors

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854287.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Lesmes D, Laster Z: Plasmacytoma in the temporomandibular joint: a case report. Br J Oral Maxillofac Surg; 2008 Jun;46(4):322-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoma in the temporomandibular joint: a case report.
  • We report a case of a 64-year-old patient in whom limitation of mouth opening was the presenting symptom of plasmacytoma.
  • Intra-oral biopsy confirmed a plasma-cell tumour, with no sign of extension on imaging.
  • The diagnosis of solitary plasmacytoma of bone can be confirmed only when the presence of systemic disease has been excluded by clinical, biological, and radiological investigations.
  • Long-term follow-up is necessary because of the high risk of development of multiple myeloma, which may be delayed.
  • [MeSH-major] Plasmacytoma / pathology. Temporomandibular Joint Disorders / pathology

  • MedlinePlus Health Information. consumer health - Temporomandibular Joint Dysfunction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698264.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


27. Rattican D, Kelly DL, Filler KA, Lyon DE: Back pain caused by a solitary plasmacytoma of bone. Clin J Oncol Nurs; 2010 Apr;14(2):149-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Back pain caused by a solitary plasmacytoma of bone.
  • This article presents initial diagnostic workup and criteria for diagnosing solitary plasmacytoma of bone (SPB) versus multiple myeloma.
  • The authors discuss the incorporation of current imaging technologies into the diagnosis and staging of SPB and multiple myeloma.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350888.001).
  • [ISSN] 1538-067X
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA127446-04; United States / NCI NIH HHS / CA / R01 CA127446; United States / NCI NIH HHS / CA / R01 CA127446-04
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS282312; NLM/ PMC4881281
  •  go-up   go-down


28. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M: The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer; 2010 Jan 1;126(1):239-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nitrogen-containing bisphosphonates (N-BPs) are effective antiosteolytic agents in patients with multiple myeloma.
  • Preclinical studies have also demonstrated that these agents have direct antitumor effects in vitro and can reduce tumor burden in a variety of animal models, although it is not clear whether such effects are caused by direct actions on tumor cells or by inhibition of bone resorption.
  • N-BPs prevent bone destruction in myeloma by inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts, thereby preventing the prenylation of small GTPase signaling proteins.
  • In this study, utilizing a plasmacytoma xenograft model without complicating skeletal lesions, treatment with zoledronic acid (ZOL) led to significant prolongation of survival in severe combined immunodeficiency mice inoculated with human INA-6 plasma cells.
  • Following treatment with a clinically relevant dose of ZOL, histological analysis of INA-6 tumors from the peritoneal cavity revealed extensive areas of apoptosis associated with poly (ADP-ribose) polymerase cleavage.
  • Furthermore, Western blot analysis of tumor homogenates demonstrated the accumulation of unprenylated Rap1A, indicative of the uptake of ZOL by nonskeletal tumors and inhibition of farnesyl pyrophosphate synthase.
  • These studies provide, for the first time, clear evidence that N-BPs have direct antitumor effects in plasma cell tumors in vivo and this is executed by a molecular mechanism similar to that observed in osteoclasts.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Female. Humans. Mice. Mice, SCID. Protein Prenylation. Transplantation, Heterologous


29. Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK: Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood; 2009 Apr 23;113(17):4027-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
  • As multiple myeloma tumors universally dysregulate cyclin D genes we conducted high-throughput chemical library screens for compounds that induce suppression of cyclin D2 promoter transcription.
  • By inhibiting both IKK and the proteosome, pristimerin causes overt suppression of constitutive NF-kappaB activity in myeloma cells that may mediate its suppression of cyclin D.
  • Multiple myeloma is exquisitely sensitive to proteosome or NF-kappaB pathway inhibition.
  • Consistent with this, pristimerin is potently and selectively lethal to primary myeloma cells (IC(50) < 100 nM), inhibits xenografted plasmacytoma tumors in mice, and is synergistically cytotoxic with bortezomib--providing the rationale for pharmaceutical development of triterpenoid dual-function proteosome/NF-kappaB inhibitors as therapeutics for human multiple myeloma and related malignancies.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biological Products / pharmacology. Chymases / antagonists & inhibitors. Multiple Myeloma / metabolism. NF-kappa B / antagonists & inhibitors. Proteasome Inhibitors. Triterpenes / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Cell Lineage. Cells, Cultured. Coculture Techniques. Combinatorial Chemistry Techniques. Cyclin D. Cyclins / genetics. Cyclins / metabolism. Drug Screening Assays, Antitumor. Enzyme Activation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Molecular Structure. Proteasome Endopeptidase Complex / metabolism. Transcriptional Activation / drug effects. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2003 Sep 15;171(6):3278-86 [12960358.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4375-83 [12907607.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):1365-77 [14729979.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):39-45 [14749474.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):191-9 [14998494.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3158-66 [15070698.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3501-8 [15116089.001]
  • [Cites] Br J Haematol. 1997 May;97(2):429-40 [9163610.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):637-46 [9531328.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):336-41 [9927043.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8505-10 [10411905.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Bioorg Med Chem Lett. 2005 May 2;15(9):2215-9 [15837296.001]
  • [Cites] Blood. 2005 Jul 1;106(1):296-303 [15755896.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9287-93 [16230390.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):407-19 [16286248.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):317-28 [16505105.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1828-38 [16551868.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4907-16 [16507771.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1452-8 [16818503.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 15;72(10):1311-21 [16984800.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):11-20 [16964520.001]
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):35764-9 [16998237.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3232-9 [17148759.001]
  • [Cites] Int Immunopharmacol. 2007 Mar;7(3):313-20 [17276889.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):357-69 [17446857.001]
  • [Cites] Neurosci Lett. 2007 Jun 21;421(1):37-41 [17548155.001]
  • [Cites] PLoS One. 2007;2(6):e559 [17593960.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):115-30 [17692804.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):131-44 [17692805.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3517-25 [17673602.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4047-54 [17875808.001]
  • [Cites] Mol Endocrinol. 2008 Jan;22(1):186-95 [17885204.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1654-64 [18006697.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):595-600 [18288389.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1750-64 [18431519.001]
  • [Cites] Cell Mol Life Sci. 2008 Oct;65(19):2979-99 [18516495.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):279-86 [11703322.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7545-56 [12386817.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1371-6 [12649201.001]
  • [Cites] Apoptosis. 2003 Aug;8(4):337-43 [12815276.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2122-9 [12931220.001]
  • (PMID = 19096011.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA133115
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biological Products; 0 / Cyclin D; 0 / Cyclins; 0 / NF-kappa B; 0 / Proteasome Inhibitors; 0 / Triterpenes; 1258-84-0 / pristimerin; EC 3.4.21.39 / Chymases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC3952546
  •  go-up   go-down


30. Van Wettere AJ, Linder KE, Suter SE, Olby NJ: Solitary intracerebral plasmacytoma in a dog: microscopic, immunohistochemical, and molecular features. Vet Pathol; 2009 Sep;46(5):949-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intracerebral plasmacytoma in a dog: microscopic, immunohistochemical, and molecular features.
  • A primary intracerebral plasmacytoma was identified in a 7-year-old spayed female Boston Terrier.
  • Grossly, a well-demarcated, 2 cm in diameter, roughly spherical tumor was in the rostral aspect of the left cerebral hemisphere.
  • Clonally rearranged B-cell antigen receptor genes were detected by PARR (polymerase chain reaction for antigen receptor rearrangements), confirming clonal proliferation of B lymphocytes.
  • Although primary solitary intracerebral plasmacytoma is rare in dogs and other species, it should be included in the differential diagnosis for central nervous system round-cell neoplasms.
  • Clonality testing can be utilized to support the histological diagnosis of this neoplasm type.
  • [MeSH-major] Brain Neoplasms / veterinary. Dog Diseases / pathology. Plasmacytoma / veterinary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19429998.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Iagaru A, Mari C, Segall G: F-18 FDG PET evaluation of bronchial plasmacytoma with CT and MRI correlation. Clin Nucl Med; 2006 May;31(5):279-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET evaluation of bronchial plasmacytoma with CT and MRI correlation.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Fluorodeoxyglucose F18. Magnetic Resonance Imaging. Plasmacytoma / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Radiopharmaceuticals. Statistics as Topic

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622337.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Nair B: Solitary extramedullary and bone plasmacytomas versus multiple myeloma with extramedullary manifestation. Oncology (Williston Park); 2010 Aug;24(9):836
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary extramedullary and bone plasmacytomas versus multiple myeloma with extramedullary manifestation.
  • [MeSH-major] Bone Neoplasms. Multiple Myeloma. Plasmacytoma
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone and Bones / pathology. Combined Modality Therapy. Humans. Radiotherapy. Survival Analysis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2010 Aug;24(9):832-5 [20923037.001]
  • (PMID = 20923038.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


33. Kondo H, Takada M, Shibuya H, Shirai W, Matsuo K, Sato T: Cutaneous plasmacytoma in three golden hamsters (Mesocrietus auratus). J Vet Med A Physiol Pathol Clin Med; 2006 Mar;53(2):74-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous plasmacytoma in three golden hamsters (Mesocrietus auratus).
  • Spontaneously occurring cutaneous tumours in three golden hamsters were characterized using histological, immunohistochemical and ultrastructural methods.
  • Histologically, the tumours were composed of sheets of round to oval plasmacytoid cells with eccentrically placed nuclei.
  • BLA positivity and characteristics of ultrastructure showed the plasma cell origin.
  • [MeSH-major] Mesocricetus. Plasmacytoma / veterinary. Rodent Diseases / pathology. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466459.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Hagiyama M, Ichiyanagi N, Kimura KB, Murakami Y, Ito A: Expression of a soluble isoform of cell adhesion molecule 1 in the brain and its involvement in directional neurite outgrowth. Am J Pathol; 2009 Jun;174(6):2278-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a soluble isoform of cell adhesion molecule 1 in the brain and its involvement in directional neurite outgrowth.
  • Cell adhesion molecule 1 (CADM1), an immunoglobulin superfamily member, is expressed on superior cervical ganglion neurites and mediates cell-cell adhesion by trans-homophilic binding.
  • Murine plasmacytoma cells, P3U1, were modified to secrete sCADM1 fused with either immunoglobulin (Ig)G Fc portion (sCADM1-Fc) or its deletion form that lacks the immunoglobulin-like domain (DeltasCADM1-Fc).

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 2006 Jan;87(1):139-50 [16311015.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):9040-53 [16199880.001]
  • [Cites] Development. 2006 Mar;133(5):845-53 [16439477.001]
  • [Cites] Curr Opin Neurobiol. 2006 Feb;16(1):52-8 [16387488.001]
  • [Cites] Nat Neurosci. 2007 Jan;10(1):19-26 [17189949.001]
  • [Cites] J Neurosci. 2008 Apr 23;28(17):4414-22 [18434520.001]
  • [Cites] Lab Invest. 2008 May;88(5):504-14 [18332875.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1544-54 [18471525.001]
  • [Cites] J Smooth Muscle Res. 2008 Apr;44(2):83-93 [18552455.001]
  • [Cites] J Cell Biol. 2008 Jun 16;181(6):985-98 [18541705.001]
  • [Cites] EMBO J. 2000 Feb 15;19(4):562-71 [10675325.001]
  • [Cites] Mol Cell Neurosci. 2000 Oct;16(4):283-95 [11085868.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):427-30 [11279526.001]
  • [Cites] Mol Reprod Dev. 2001 Oct;60(2):158-64 [11553913.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):661-73 [11706054.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1525-31 [12202822.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2601-8 [12456501.001]
  • [Cites] Biol Reprod. 2003 May;68(5):1755-63 [12606335.001]
  • [Cites] Lab Invest. 2003 Aug;83(8):1175-83 [12920246.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35421-7 [12826663.001]
  • [Cites] J Neuroimmunol. 2004 Jan;146(1-2):1-12 [14698841.001]
  • [Cites] Histol Histopathol. 2004 Apr;19(2):391-400 [15024700.001]
  • [Cites] EMBO Rep. 2004 Apr;5(4):356-61 [15060572.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16083-90 [14761956.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5687-92 [15184876.001]
  • [Cites] Neuron. 1989 Jun;2(6):1597-603 [2627381.001]
  • [Cites] Int J Tissue React. 1996;18(1):1-21 [8880375.001]
  • [Cites] Neuroreport. 1997 Sep 29;8(14):3157-62 [9331933.001]
  • [Cites] Cell Cycle. 2005 Mar;4(3):e131-5 [15725728.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6934-42 [15905536.001]
  • [Cites] Trends Neurosci. 2006 Jan;29(1):21-9 [16337696.001]
  • (PMID = 19435791.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 126547-89-5 / Intercellular Adhesion Molecule-1
  • [Other-IDs] NLM/ PMC2684192
  •  go-up   go-down


35. Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S: IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood; 2010 Mar 4;115(9):1746-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-6 and MYC collaborate in plasma cell tumor formation in mice.
  • Interleukin-6 (IL-6) plays a critical role in the natural history of human plasma cell neoplasms (PCNs), such as plasma cell myeloma and plasmacytoma (PCT).
  • IL-6 is also at the center of neoplastic plasma cell transformation in BALB/c (C) mice carrying a transgene, H2-L(d)-IL6, that encodes human IL-6 under control of the major histocompatibility complex H2-L(d) promoter: strain C.H2-L(d)-IL6.
  • These mice are prone to PCT, but tumor development is incomplete with long latencies ( approximately 40% PCT at 12 months of age).
  • We found that double-transgenic C.H2-L(d)-IL6/iMyc(Emu) and C.H2-L(d)-IL6/iMyc(Calpha) mice develop PCT with full penetrance (100% tumor incidence) and short latencies (3-6 months).
  • The mouse tumors mimic molecular hallmarks of their human tumor counterparts, including elevated IL-6/Stat3/Bcl-X(L) signaling.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Jul 1;80(1):194-202 [1611085.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):997-1000 [2388041.001]
  • [Cites] Nature. 1994 Mar 24;368(6469):339-42 [8127368.001]
  • [Cites] Blood. 1995 Feb 15;85(4):863-72 [7849308.001]
  • [Cites] J Exp Med. 1995 Jul 1;182(1):243-8 [7790819.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):689-96 [9284817.001]
  • [Cites] J Nat Prod. 2004 Dec;67(12):2070-2 [15620253.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1306-15 [15735016.001]
  • [Cites] Annu Rev Immunol. 2005;23:1-21 [15771564.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):137-46 [15751044.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4251-8 [15930364.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7644-52 [16140930.001]
  • [Cites] J Pathol. 2006 May;209(1):44-55 [16482495.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):871-5 [17283116.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2439-47 [17363561.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):153-9 [17593022.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3771-5 [17606706.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):585-98 [17646864.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4987-98 [17310994.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1911-28 [17849470.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6469-78 [17975159.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Dec;21(6):1051-69, viii [17996588.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1021-8 [17989316.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):167-80 [18242516.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2519-26 [18451212.001]
  • [Cites] Anticancer Drugs. 2008 Sep;19(8):777-82 [18690088.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):1949-57 [18678733.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6414-25 [18927280.001]
  • [Cites] Exp Cell Res. 2009 Feb 1;315(3):485-97 [19071109.001]
  • [Cites] Blood. 2009 Jan 22;113(4):846-55 [18948577.001]
  • [Cites] Mayo Clin Proc. 2009 Feb;84(2):114-22 [19181644.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Leukemia. 2000 May;14(5):909-21 [10803525.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1127-35 [10865979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1509-14 [11805288.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1182-8 [12040451.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4319-23 [12409330.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2285-95 [12700664.001]
  • [Cites] Immunol Rev. 2003 Aug;194:177-95 [12846815.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):95-105 [12953802.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4653-65 [14581334.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9007-21 [14663479.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14982-7 [14634209.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8656-63 [14695177.001]
  • [Cites] J Clin Invest. 2004 Jun;113(12):1763-73 [15199411.001]
  • [Cites] EMBO J. 1990 Mar;9(3):897-905 [2155783.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7361-5 [8346257.001]
  • (PMID = 20018915.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P50CA097274; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / IL6 protein, human; 0 / Interleukin-6
  • [Other-IDs] NLM/ PMC2832814
  •  go-up   go-down


36. García PA, Guillén MM, Checa CM, Rubio LD: Solitary intravascular plasmacytoma. Am J Hematol; 2010 May;85(5):393-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intravascular plasmacytoma.
  • [MeSH-major] Plasmacytoma / pathology. Plasmacytoma / radiography. Pulmonary Artery / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425805.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


37. Shuaipaj T, Abutalib SA, Chen YH, Gaitonde S, Lindgren V: Intracranial plasmacytoma mimicking meningioma in a patient with Castleman's disease. Am J Hematol; 2009 Mar;84(3):195-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial plasmacytoma mimicking meningioma in a patient with Castleman's disease.
  • [MeSH-major] Brain Neoplasms / pathology. Giant Lymph Node Hyperplasia / complications. Plasmacytoma / complications. Plasmacytoma / pathology


38. Subhas N, Bauer TW, Joyce MJ, Sundaram M: The "mini brain" appearance of plasmacytoma in the appendicular skeleton. Skeletal Radiol; 2008 Aug;37(8):771-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "mini brain" appearance of plasmacytoma in the appendicular skeleton.
  • We report on the case of a 70-year-old woman presenting with right hip pain.
  • The MRI appearance resembled that of a small brain or "mini brain".
  • Biopsy specimen demonstrated predominantly mature plasma cells, with occasional admixed immature forms.
  • A diagnosis of plasmacytosis, consistent with myeloma, was made.
  • This case illustrates a rare but seemingly characteristic "mini brain" appearance of plasmacytoma, which, to date, has only been reported in the spine and has not been observed in other bony lesions.
  • [MeSH-major] Femoral Neoplasms / diagnosis. Plasmacytoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Sep 15;90(6):2127-47 [9310464.001]
  • [Cites] Orthop Clin North Am. 1985 Jul;16(3):445-59 [4011162.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1311-5 [8315427.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):261-3 [10882284.001]
  • [Cites] Acta Oncol. 2000;39(7):823-7 [11145440.001]
  • (PMID = 18470512.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Sugimoto Y, Nishii K, Miyata E, Fujieda A, Yamaguchi M, Masuya M, Katayama N: [Multiple myeloma relapsed or progressed as plasmacytoma after allogeneic reduced-intensity stem cell transplantation: report of three cases]. Rinsho Ketsueki; 2009 Apr;50(4):289-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple myeloma relapsed or progressed as plasmacytoma after allogeneic reduced-intensity stem cell transplantation: report of three cases].
  • Autologous peripheral blood stem cell transplantation (auto-PBSCT) is considered the standard therapy for younger patients with multiple myeloma, however, survival curve doesn't reach plateau.
  • On the other hand, allogeneic reduced-intensity stem cell transplantation (RIST) with graft-versus-myeloma (GVM) effects is expected to be the curable therapy.
  • All of three cases relapsing or progressing after RIST showed disease type of plasmacytoma without plasma cells in the bone marrow.
  • That may be because conditioning regimen doesn't include total body irradiation, or GVM is ineffective in plasmacytoma, but effective in bone marrow.
  • Here, we report clinical course of these three cases with some consideration.
  • [MeSH-major] Graft vs Tumor Effect. Multiple Myeloma / therapy. Plasmacytoma / etiology. Stem Cell Transplantation. Transplantation Conditioning. Transplantation, Homologous
  • [MeSH-minor] Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404022.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Glass J: Neurologic complications of lymphoma and leukemia. Semin Oncol; 2006 Jun;33(3):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular occlusion may occur as a result of blockage of blood vessels by tumor cells.
  • A variety of paraneoplastic syndromes occur and are most commonly associated with plasma cell tumors.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769423.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


41. Malhotra P, Bhat P, Mahi S, Chauhan S, Rajwanshi A, Varma S: Evolution of hepatosplenic plasmacytoma in a patient with multiple myeloma receiving chemotherapy. Am J Hematol; 2005 Jan;78(1):82-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of hepatosplenic plasmacytoma in a patient with multiple myeloma receiving chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Liver Neoplasms / chemically induced. Multiple Myeloma / drug therapy. Plasmacytoma / chemically induced. Splenic Neoplasms / chemically induced
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Disease Progression. Female. Humans. Melphalan / administration & dosage. Prednisolone / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609282.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  •  go-up   go-down


42. Liu ZY, Qi XQ, Wu XJ, Luo C, Lu YC: Solitary intracranial plasmacytoma located in the spheno-clival region mimicking chordoma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1868-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intracranial plasmacytoma located in the spheno-clival region mimicking chordoma: a case report.
  • Solitary intracranial plasmacytoma (SIP) is very rare.
  • Based on the initial diagnosis of a spheno-clival region chordoma, the tumour was partially resected by the nasal-sphenoidal sinus approach.
  • Subsequently, the correct diagnosis of SIP was made based on the pathology and immunohistochemical staining of the tumour.
  • The findings of a series of similar case reports documenting SIP in 20 cases published from 1976 to 2008 are also reviewed.
  • Based on these case reports, the key features of SIP, including their clinical manifestations, clinical imaging characteristics, treatment and prognosis, are described.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chordoma / diagnosis. Cranial Fossa, Posterior / pathology. Plasmacytoma / diagnosis. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309504.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Marotta S, Di Micco P: Solitary plasmacytoma of the jaw. J Blood Med; 2010;1:33-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of the jaw.
  • Solitary plasmacytoma may be considered as a rare neoplasm of head and neck and is a different disease compared to multiple myeloma.
  • The main difference is related to the better clinical prognosis of solitary plasmacytoma, which may be clinically silent for several years but several local recurrences may be possible once diagnosed and treated.
  • Clinical signs and symptoms of solitary plasmacytoma are related to bone pain and possible bone fractures.
  • Partial local impairment of local bone function may be present.
  • Bone swelling and local involvement of mucosa and local soft tissue may be revealed.
  • Other systemic dysfunctions as systemic bone marrow involvement with related anemia and absent thrombocytopenia.
  • However, although very rare, solitary plasmacytoma of the jaw may have several clinical presentations and here we review clinical differences reported in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22282681.001).
  • [ISSN] 1179-2736
  • [Journal-full-title] Journal of blood medicine
  • [ISO-abbreviation] J Blood Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3262320
  • [Keywords] NOTNLM ; bone function / fracture / monoclonal / multiple myeloma / solitary plasmacytoma
  •  go-up   go-down


44. Takizawa M, Kim JS, Tessarollo L, McNeil N, Waldschmidt TJ, Casellas R, Ried T, Janz S: Genetic reporter system for oncogenic Igh-Myc translocations in mice. Oncogene; 2010 Jul 15;29(28):4113-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Myc-deregulating chromosomal T(12;15)(Igh-Myc) translocation, the hallmark mutation of inflammation- and interleukin 6-dependent mouse plasmacytoma (PCT), is the premier model of cancer-associated chromosomal translocations because it is the only translocation in mice that occurs spontaneously (B lymphocyte lineage) and with predictably high incidence (approximately 85% of PCT), and has a direct counterpart in humans: Burkitt lymphoma t(8;14)(q24;q32) translocation.
  • Here, we report on the development of a genetic system for the detection of T(12;15)(Igh-Myc) translocations in plasma cells of a mouse strain in which an enhanced green fluorescent protein (GFP)-encoding reporter gene has been targeted to Myc.
  • GFP expression did not interfere with tumor development or the deregulation of Myc on derivative 12 of translocation, der (12), because the reporter gene was allocated to the reciprocal product of translocation, der (15).
  • Although the described reporter gene approach requires refinement before T(12;15) translocations can be quantitatively detected in vivo, including in B lymphocyte lineage cells that have not yet completed malignant transformation, our findings provide proof of principle that reporter gene tagging of oncogenes in gene-targeted mice can be used to elucidate unresolved questions on the occurrence, distribution and trafficking of cells that have acquired cancer-causing chromosomal translocations of great relevance for humans.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1969 Jun 7;222(5197):994-5 [5789334.001]
  • [Cites] Cell. 2004 Aug 20;118(4):431-8 [15315756.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):232-5 [1729694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7361-5 [8346257.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):419-23 [8542601.001]
  • [Cites] Blood. 1997 Jan 1;89(1):291-6 [8978304.001]
  • [Cites] J Exp Med. 1997 Sep 15;186(6):921-9 [9294146.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;224:251-5 [9308248.001]
  • [Cites] Oncogene. 1997 Nov 6;15(19):2369-77 [9393881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13588-93 [9391070.001]
  • [Cites] Semin Immunol. 2005 Dec;17(6):431-41 [16216522.001]
  • [Cites] Mol Cell. 2006 Jan 20;21(2):201-14 [16427010.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1213-24 [16815105.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Cytometry A. 2007 Aug;71(8):542-9 [17598185.001]
  • [Cites] Cell. 2008 Dec 12;135(6):1028-38 [19070574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2265-70 [19174520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2717-22 [19196992.001]
  • [Cites] Nature. 2009 Jul 9;460(7252):231-6 [19587764.001]
  • [Cites] Nature. 2009 Dec 10;462(7274):803-7 [20010689.001]
  • [Cites] Nature. 2000 Mar 30;404(6777):510-4 [10761921.001]
  • [Cites] Leukemia. 2000 May;14(5):909-21 [10803525.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1127-35 [10865979.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Genes Dev. 2001 Aug 15;15(16):2023-30 [11511533.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5580-94 [11607811.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1071-7 [12730130.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2842-50 [12743607.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8656-63 [14695177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • (PMID = 20453890.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA151354; United States / NCI NIH HHS / CA / CA151354-01; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA151354-01; United States / NCI NIH HHS / CA / P50CA097274; United States / NCI NIH HHS / CA / P50 CA097274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS297327; NLM/ PMC3108853
  •  go-up   go-down


45. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood; 2006 May 15;107(10):4053-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
  • Perifosine is a synthetic novel alkylphospholipid, a new class of antitumor agents which targets cell membranes and inhibits Akt activation.
  • Here we show that baseline phosphorylation of Akt in multiple myeloma (MM) cells is completely inhibited by perifosine [octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate] in a time- and dose-dependent fashion, without inhibiting phosphoinositide-dependent protein kinase 1 phosphorylation.
  • Perifosine induces significant cytotoxicity in both MM cell lines and patient MM cells resistant to conventional therapeutic agents.
  • Importantly, Perifosine induces apoptosis even of MM cells adherent to bone marrow stromal cells.
  • Furthermore, perifosine augments dexamethasone, doxorubicin, melphalan, and bortezomib-induced MM cell cytotoxicity.
  • Finally, perifosine demonstrates significant antitumor activity in a human plasmacytoma mouse model, associated with down-regulation of Akt phosphorylation in tumor cells.
  • Taken together, our data provide the rationale for clinical trials of perifosine to improve patient outcome in MM.


46. Thoumazet F, Donnio A, Ayeboua L, Brebion A, Diedhou A, Merle H: Orbital and muscle involvement in multiple myeloma. Can J Ophthalmol; 2006 Dec;41(6):733-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital and muscle involvement in multiple myeloma.
  • CASE REPORT: We report 2 cases of orbital plasmacytoma in patients with known multiple myeloma.
  • Case 2 is the first report of immunoglobulin A kappa light chain multiple myeloma involving orbital recti muscles.
  • Computed axial tomography and magnetic resonance imaging aided the diagnosis, confirmed with histopathologic studies.
  • From a review of the literature since 1972, we conclude that the immunoglobulin G type of multiple myeloma, whether lambda or kappa light chain, may be a risk factor for orbital involvement.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224955.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


47. Ma SL, Sørensen AB, Kunder S, Sørensen KD, Quintanilla-Martinez L, Morris DW, Schmidt J, Pedersen FS: The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus. Virology; 2006 Sep 1;352(2):306-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus.
  • By screening about 1200 murine leukemia virus (MLV)-induced lymphomas, we found proviral insertions at the Icsbp locus in 14 tumors, 13 of which were mature B-cell lymphomas or plasmacytomas.
  • Only one was a T-cell lymphoma, although such tumors constituted about half of the samples screened.
  • Since our results showed expression of Icsbp RNA and protein in all end-stage tumor samples, a simple tumor suppressor function of ICSBP is not likely.
  • Interestingly, proviral insertions at Icsbp have not been reported from previous extensive screenings of mature B-cell lymphomas induced by endogenous MLvs. We propose that ICSBP might be involved in an early modulation of an immune response to exogenous MLVs that might also play a role in proliferation of the mature B-cell lymphomas.
  • [MeSH-major] Interferon Regulatory Factors / genetics. Leukemia Virus, Murine / genetics. Leukemia Virus, Murine / pathogenicity. Lymphoma, B-Cell / virology. Plasmacytoma / virology. Virus Integration / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780917.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / interferon regulatory factor-8
  •  go-up   go-down


48. Brady-West DC, Buchner-Daley LM, McGrowder DA, Taylor-Houston J, West KA: Multiple myeloma presenting as cervical lymphadenopathy in a 16-year-old boy. J Natl Med Assoc; 2009 Aug;101(8):810-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma presenting as cervical lymphadenopathy in a 16-year-old boy.
  • A 16-year-old boy presented with cervical lymphadenopathy and histological features of a plasmacytoma.
  • He was found to have lytic bone lesions, a serum IgA M-protein, and elevated beta 2-microglobulin.
  • This was followed by complete resolution of his disease, and he remains clinically well 5 years after completion of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Lymphatic Diseases / diagnosis. Lymphatic Diseases / therapy. Multiple Myeloma / diagnosis. Multiple Myeloma / therapy


49. Sakai Y, Ikeya J, Morita I, Sato K: Extramedullary plasmacytoma of the tonsil diagnosed by fine-needle aspiration cytology. Ann Diagn Pathol; 2008 Feb;12(1):41-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary plasmacytoma of the tonsil diagnosed by fine-needle aspiration cytology.
  • A case of tonsillar extramedullary plasmacytoma in a 53-year-old man with a complaint of lump sensation in the throat is presented.
  • Cytologic smear obtained by fine-needle aspiration biopsy appeared highly cellular and was composed of clusters of plasma cells with varying maturity.
  • Atypical plasma cells had prominent eccentric nuclei with nucleoli and finely granular cytoplasm.
  • The cytoplasm of mature-looking small plasma cells was also finely granular without a perinuclear halo.
  • A cytologic diagnosis of plasmacytoma was made.
  • Metastatic examination finding was negative for multiple myeloma, and the patient was diagnosed as having extramedullary plasmacytoma.
  • Although the diagnosis of plasmacytoma on cytologic smear may be difficult, in the current case, fine-needle aspiration cytology provided a rapid and accurate diagnosis.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Plasmacytoma / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Palatine Tonsil / chemistry. Palatine Tonsil / pathology. Palatine Tonsil / surgery. Plasma Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164414.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


50. Chelly I, Mekni A, Bellil K, Belhadj Salah M, Bellil S, Haouet S, Kchir N, Horchani A, Zitouna M: [Testicular plasmocytoma: a case report]. Tunis Med; 2007 Aug;85(8):702-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular plasmocytoma: a case report].
  • [Transliterated title] Le plasmocytome testiculaire: a propos d'un cas.
  • BACKGROUND: Extramedullary plasmocytoma is rare, with less than 50 reported cases and only 8 cases of primary testicular plasmocytoma.
  • AIM: Report of a new case CASE: This report concerns a 65-year-old patient presenting an enlargement of the testis.
  • The diagnosis of testicular plasmocytoma was made on histological examination.
  • There was no evidence of bone marrow involvement or systemic signs of myeloma.
  • [MeSH-major] Plasmacytoma / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254296.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Tunisia
  • [Number-of-references] 10
  •  go-up   go-down


51. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I, Huang Y, Ogura T, Takahashi S, Ueda R, Barlogie B, Shaughnessy J Jr, Esumi H: ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene; 2005 Oct 20;24(46):6936-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
  • ARK5, AMP-activated protein kinase (AMPK)-related protein kinase mediating Akt signals, is closely involved in tumor progression, and its stage-associated expression was observed in colorectal cancer.
  • In this study, we found ARK5 expression in multiple myeloma cell lines expressing c-MAF and MAFB.
  • In addition, gene expression profiling of 351 clinical specimens revealed ARK5 expression in primary myelomas expressing c-MAF and MAFB, suggesting that ARK5 may be a transcriptional target of the Large-MAF family.
  • Moreover, in ARK5 mRNA-expressing multiple myeloma lines, but not in ARK5-negative lines, insulin-like growth factor (IGF)-1 increased invasion activity.
  • IGF-1-induced invasion was reproduced when ARK5 was overexpressed in Burkitt's lymphoma and plasmacytoma lines.
  • Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / physiology. Maf Transcription Factors, Large / physiology. Multiple Myeloma / genetics. Protein Kinases / genetics. Repressor Proteins / genetics. Transcription, Genetic / physiology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA Primers. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044163.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA55819; United States / NCI NIH HHS / CA / CA97513
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Maf Transcription Factors, Large; 0 / Repressor Proteins; EC 2.7.- / Protein Kinases; EC 2.7.1.- / NUAK1 protein, human
  •  go-up   go-down


52. Iseri M, Ozturk M, Ulubil SA: Synchronous presentation of extramedullary plasmacytoma in the nasopharynx and the larynx. Ear Nose Throat J; 2009 Nov;88(11):E9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous presentation of extramedullary plasmacytoma in the nasopharynx and the larynx.
  • Simultaneous extramedullary plasmacytoma of the nasopharynx and larynx is exceedingly rare; to the best of our knowledge, only 1 other case has been previously reported.
  • At 2 years of follow-up, no evidence of recurrence or progression to multiple myeloma was noted.
  • We discuss the clinical features and treatment of plasma cell neoplasms in general and their three variants in particular.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Larynx / pathology. Nasopharyngeal Neoplasms / diagnosis. Nasopharynx / pathology. Plasmacytoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19924656.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Park SS, Shaffer AL, Kim JS, duBois W, Potter M, Staudt LM, Janz S: Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. Cancer Res; 2005 Sep 1;65(17):7644-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.
  • Gene-targeted mice that contain a His6-tagged mouse c-Myc cDNA, Myc(His), inserted head to head into different sites of the mouse immunoglobulin heavy-chain locus, Igh, mimic the chromosomal T(12;15)(Igh-Myc) translocation that results in the activation of Myc in the great majority of mouse plasmacytomas.
  • Mice carrying Myc(His) just 5' of the intronic heavy-chain enhancer Emu (strain iMyc(Emu)) provide a specific model of the type of T(12;15) found in a subset (approximately 20%) of plasmacytomas that develop "spontaneously" in the gut-associated lymphoid tissue (GALT) of interleukin-6 transgenic BALB/c (C) mice.
  • Here we show that the transfer of the iMyc(Emu) transgene from a mixed genetic background of segregating C57BL/6 x 129/SvJ alleles to the background of C increased the incidence of GALT plasmacytomas by a factor of 2.5 in first-generation backcross mice (C.iMyc(Emu) N1).
  • Third-generation backcross mice (C.iMyc(Emu) N3, approximately 94% C alleles) were hypersusceptible to inflammation-induced peritoneal plasmacytomas (tumor incidence, 100%; mean tumor onset, 86 +/- 28 days) compared with inbred C mice (tumor incidence, 5% on day 150 after tumor induction).
  • Peritoneal plasmacytomas of C.iMyc(Emu) N3 mice overexpressed Myc(His), produced monoclonal immunoglobulin, and exhibited a unique plasma cell signature upon gene expression profiling on mouse Lymphochip cDNA microarrays.
  • These findings indicated that the iMyc(Emu) transgene accelerates plasmacytoma development by collaborating with tumor susceptibility alleles of strain C and circumventing the requirement for tumor precursors to acquire deregulated Myc by chromosomal translocation.
  • [MeSH-major] Genes, Immunoglobulin / genetics. Genes, myc / genetics. Peritoneal Neoplasms / genetics. Plasmacytoma / genetics


54. Kalyani A, Rohaizak M, Cheong SK, Nor Aini U, Balasundaram V, Norlia A: Recurrent multiple myeloma presenting as a breast plasmacytoma. Med J Malaysia; 2010 Sep;65(3):227-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent multiple myeloma presenting as a breast plasmacytoma.
  • We describe a patient with multiple myeloma, who initially responded to chemotherapy and went into remission.
  • She presented 10 months later with a right breast lump which was confirmed by core biopsy to be a plasmacytoma.
  • Further treatment with radiotherapy, thalidomide and later second line chemotherapy appeared unsuccessful and she showed rapid disease progression with rising paraproteins and new extramedullary plasmacytoma lesions in the forehead, supraclavicular region, nasopharynx, liver, spleen, pancreas and paraaortic lymph nodes.
  • [MeSH-major] Breast Neoplasms / pathology. Multiple Myeloma / pathology. Neoplasm Recurrence, Local / pathology. Plasmacytoma / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21939175.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


55. Paubelle E, Coppo P, Garderet L, Azizi L, Bories D, Gorin NC, Fouillard L: Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia; 2005 Sep;19(9):1702-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect.
  • [MeSH-major] Boronic Acids / therapeutic use. Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Multiple Myeloma / drug therapy. Plasmacytoma / drug therapy. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001088.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


56. Urkijo JC, Blanco MS, Unzurrunzaga A, Ojanguren JM, Díaz F, Mendoza MF, de la Viuda JM: Polyarthritis associated with monoclonal gammopathy: an unusual case with plasmacytoma. J Clin Rheumatol; 2007 Aug;13(4):240-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyarthritis associated with monoclonal gammopathy: an unusual case with plasmacytoma.
  • [MeSH-major] Arthritis / etiology. Paraproteinemias / etiology. Plasmacytoma / complications

  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762467.001).
  • [ISSN] 1076-1608
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Huang CC, Liu MT, Pi CP, Chung CY: Primary plasmacytoma of the uterine cervix treated with three-dimensional conformal radiotherapy. Singapore Med J; 2008 Dec;49(12):e361-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasmacytoma of the uterine cervix treated with three-dimensional conformal radiotherapy.
  • Primary plasmacytoma of the uterine cervix is a rare neoplasm with limited known data, and only several cases sporadically reported in the published literature.
  • Radiotherapy might have a role in the treatment of plasmacytoma of the uterine cervix.
  • We describe primary plasmacytoma of the uterine cervix in a 45-year-old woman treated with three-dimensional conformal radiotherapy, and also reviewed the literature to evaluate the treatment modality and therapeutic outcome of this rare disease.
  • [MeSH-major] Plasmacytoma / radiotherapy. Radiotherapy, Conformal. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122936.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


58. Omoti AE, Omoti CE: Ophthalmic manifestations of multiple myeloma. West Afr J Med; 2007 Oct-Dec;26(4):265-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ophthalmic manifestations of multiple myeloma.
  • BACKGROUND: The ophthalmic manifestations of multiple myeloma can be seen in practically every ocular structure.
  • Ocular findings may be the first manifestations of the disease.
  • It may also occur as one of the extramedullary manifestations of the disease or as the first sign of insufficient chemotherapy.
  • Multiple myeloma may cause ocular pathology by direct infiltration or as extramedullary plasmacytomas resulting in displacement or compression of tissues, by causing hyperviscosity syndrome, and by immunoglobulin light chain deposition in ocular tissues.
  • OBJECTIVE: To outline the ophthalmic manifestations of multiple myeloma.
  • METHODS: Information about multiple myeloma and ophthalmic manifestations was obtained from original journal articles, review articles, case reports and standard postgraduate textbooks.
  • RESULTS: Ophthalmic manifestations include proptosis, diplopia, lid ecchymosis, xanthomatosis, conjunctival and corneal crystalline and non-crystalline deposits, scleritis, episcleritis, secondary glaucoma, ciliary body cysts, ciliochoroidal effusion, uveal plasmacytoma, hyperviscosity retinopathy, retinal vasculitis, detachment of sensory retina and retinal pigment epithelium, and neuro-ophthalmic manifestations.
  • CONCLUSIONS: In multiple myeloma, it is necessary to take a closer look at the ophthalmic manifestations, both because of their local morbidity and because they might act as a reservoir for proliferation of myeloma cells and eventual systemic relapse.
  • All patients with multiple myeloma should thus undergo thorough ophthalmic examination at the time of initial diagnosis and during follow-up.
  • [MeSH-major] Eye Diseases / pathology. Multiple Myeloma / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705423.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 39
  •  go-up   go-down


59. Chao MW, Gibbs P, Wirth A, Quong G, Guiney MJ, Liew KH: Radiotherapy in the management of solitary extramedullary plasmacytoma. Intern Med J; 2005 Apr;35(4):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy in the management of solitary extramedullary plasmacytoma.
  • BACKGROUND: Solitary extramedullary plasmacytoma (SEP) is a rare tumour for which the standard treatment remains local radiotherapy (RT).
  • We present a study of a multi-institutional experience, between 1980 and 1999, in an attempt to better understand the natural history of SEP and to identify possible prognostic factors.
  • The inclusion criteria were as follows: (i) histological confirmation of clonal plasma cells involving a single extramedullary site with or without lymph node involvement;.
  • (ii) no histological evidence of bone marrow involvement;.
  • (iii) no evidence of distant bone lesion on radiographic skeletal survey (bone erosions adjacent to the primary thought to be due to contiguous involvement were permitted) and (iv) no anaemia, hypercalcaemia or renal impairment due to plasma cell dyscrasia.
  • Among all patients, a serum mono-clonal paraprotein was found in three patients and bone erosion was identified in seven patients.
  • Multiple myeloma (MM) developed in five patients, all within 5 years.
  • The predicted 10-year myeloma free survival is 75% and 10-year overall survival is 54%.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Head and Neck Neoplasms / radiotherapy. Plasmacytoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15836498.001).
  • [ISSN] 1444-0903
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Australia
  •  go-up   go-down


60. Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst; 2006 Mar;11(1):9-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
  • BACKGROUND: Paraprotein-associated neuropathies have heterogeneous clinical, neurophysiological, neuropathological, and hematological features.
  • OBJECTIVES: The aim of this guideline was to prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein [paraproteinemic demyelinating neuropathy (PDN)].
  • METHODS: Disease experts and a representative of patients considered references retrieved from MEDLINE and the Cochrane Library and prepared statements that were agreed in an iterative fashion.
  • (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia;.
  • (2) the paraprotein is more likely to be causing the neuropathy if the paraprotein is immunoglobulin M (IgM), antibodies are present in serum or on biopsy, or the clinical phenotype is chronic distal sensory neuropathy;.
  • Their potential benefit should be balanced against their possible side effects and the usually slow disease progression;.
  • (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy clinically, electrophysiologically, and in response to treatment; and (6) for POEMS syndrome, local irradiation or resection of an isolated plasmacytoma, or melphalan with or without corticosteroids, should be considered, with hemato-oncology advice.
  • [MeSH-major] Paraproteinemias / diagnosis. Paraproteinemias / therapy. Polyradiculoneuropathy / diagnosis. Polyradiculoneuropathy / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519778.001).
  • [ISSN] 1085-9489
  • [Journal-full-title] Journal of the peripheral nervous system : JPNS
  • [ISO-abbreviation] J. Peripher. Nerv. Syst.
  • [Language] eng
  • [Publication-type] Guideline; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Valbuena JR, Rassidakis GZ, Lin P, Atwell C, Georgakis GV, Younes A, Jones D, Medeiros LJ: Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol; 2005 Oct;18(10):1343-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heat-shock protein-90 (HSP90) inhibitors are currently being used in phase I clinical trials for treating patients with a variety of neoplasms including lymphomas.
  • In B-cell lymphomas, HSP90 was moderately to strongly expressed in all cases of Burkitt's lymphoma (5/5, 100%), and in subsets of follicular lymphoma (17/28, 61%), diffuse large B-cell lymphoma (27/46, 59%), nodal marginal zone B-cell lymphoma (6/16, 38%), plasma cell neoplasms (14/39, 36%), small lymphocytic lymphoma/chronic lymphocytic leukemia (3/9, 33%), mantle cell lymphoma (12/38, 32%) and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (3/10, 30%).
  • HSP90 was weakly expressed in six of 14 (43%) cases of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • In T-cell lymphomas, HSP90 was moderately to strongly expressed in subsets of anaplastic large-cell lymphoma (14/24, 58%; 9/12 ALK+ and 5/12 ALK-), precursor-T-cell lymphoblastic leukemia/lymphoma (20/65, 31%), unspecified peripheral T-cell lymphoma (8/43, 23%) and angioimmunoblastic T-cell lymphoma (2/17, 12%).
  • We conclude that HSP90 is commonly expressed in a subset of many types of B- and T-cell lymphoma.
  • [MeSH-minor] Cell Line, Tumor. Humans. Lymph Nodes / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, T-Cell / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16056252.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins
  •  go-up   go-down


62. Bhat RV, Prathima K, Harendra Kumar M, Narayana G: Plasmacytoma of tonsil diagnosed by fine-needle aspiration cytology. J Cytol; 2010 Jul;27(3):102-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoma of tonsil diagnosed by fine-needle aspiration cytology.
  • Extramedullary plasmacytoma of tonsil is rare.
  • Even though biopsy is necessary for final diagnosis, fine-needle aspiration cytology (FNAC) can provide useful information in the management of such cases.
  • We report a case of plasmacytoma of tonsil diagnosed by FNAC in a 43-year-old man who presented with a swelling in the right tonsillar area.
  • FNAC smears revealed sheets of plasma cells at various stages of maturation.
  • Subsequent histopathological and immunohistochemical studies confirmed the diagnosis of plasmacytoma.
  • This case is reported for the rarity of site for extramedullary plasmacytoma and to highlight the usefulness of FNAC in lesions of tonsil.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187876.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2983074
  • [Keywords] NOTNLM ; FNAC / Plasmacytoma / tonsil
  •  go-up   go-down


63. Liu ML, Kallakury B, Kessler C, Hartmann DP, Azumi N, Ozdemirli M: Chronic idiopathic myelofibrosis terminating in extramedullary anaplastic plasmacytoma. Leuk Lymphoma; 2006 Feb;47(2):315-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic idiopathic myelofibrosis terminating in extramedullary anaplastic plasmacytoma.
  • Chronic idiopathic myelofibrosis (CIMF) is a chronic myeloproliferative disorder (CMPD) with progressive fibrosis and extramedullary hematopoiesis.
  • Similar to other CMPDs, the stem cell in CIMF has the potential to differentiate into myeloid or lymphoid lineages, and thus CIMF can culminate in acute leukemia of myeloid or, rarely, lymphoid lineage.
  • We describe an unusual case of CIMF terminating in extramedullary anaplastic plasmacytoma.
  • Flow cytometric and immunohistochemical analysis demonstrated plasma cell-related antigens (CD138, CD38, cytoplasmic kappa light chain), epithelial membrane antigen and CD43 in the tumor cells.
  • The myeloid, B-cell or T-cell markers were negative.
  • The plasma cell origin was further confirmed by electron microscopic examination, which revealed stacks of rough endoplasmic reticulum.
  • Monoclonal gammopathy may occur in CIMF, and rare cases of simultaneous plasma cell myeloma and CIMF have been reported in the literature.
  • However, to the best of our knowledge, this is the first report of CIMF terminating in extramedullary anaplastic plasmacytoma.
  • [MeSH-major] Hematopoiesis, Extramedullary. Plasmacytoma / pathology. Primary Myelofibrosis / pathology
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Chronic Disease. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Middle Aged. Spleen / pathology


64. Soubrier M: [POEMS syndrome]. Presse Med; 2007 Nov;36(11 Pt 2):1676-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The POEMS syndrome combines a constant polyneuropathy (P), organomegaly (O), endocrinopathy (E), monoclonal gammopathy (M) (or other plasma cell disorder) and skin changes (S).
  • Consistent plasma cell disorders include a monoclonal component, often in small quantities with a lambda light chain isotype, and plasmacytoma, often solitary lesions.
  • Treatment depends on specific characteristics of the disease and the patient (radiation therapy for plasmocytoma, autologous bone marrow transplantation in young subjects, corticosteroid therapy or chemotherapy in the elderly).

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629447.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 28
  •  go-up   go-down


65. Salarieh A, Rao C, Gottesman SR, Alagha O, Todor R, Axiotis CA: Plasma cell tumors in HIV-positive patients: report of a case and review of the literature. Leuk Lymphoma; 2005 Jul;46(7):1067-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell tumors in HIV-positive patients: report of a case and review of the literature.
  • Plasma cell tumors show an increased incidence in HIV-positive patients.
  • The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population.
  • Pathologically, many of these tumors show a plasmablastic morphology.
  • Plasma cell tumors in HIV-positive patients may present at unusual sites and progress rapidly to involve multiple sites, including the soft tissues and viscera.
  • A case of plasma cell tumor in an HIV-positive patient is presented.
  • [MeSH-major] Brain Neoplasms / complications. HIV Seropositivity / complications. Plasmacytoma / complications


66. Dave BR, Nanda A, Anandjiwala JV: Transpedicular percutaneous biopsy of vertebral body lesions: a series of 71 cases. Spinal Cord; 2009 May;47(5):384-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy specimens were obtained by passing a self-designed 5-mm diameter biopsy instrument through the pedicle into the site of the disease using C-arm fluoroscopy.
  • The pathologic examinations revealed infections in 25, osteoporotic wedging in 21, metastasis in eight, plasmacytoma in three, multiple myeloma in four, non-Hodgkin's lymphoma in one and round cell tumor in one patient.
  • Diagnosis was established in 63 of 71 patients (88.7%).
  • [MeSH-major] Biopsy, Needle / methods. Lumbar Vertebrae / pathology. Spinal Diseases / diagnosis. Spinal Diseases / pathology. Thoracic Vertebrae / pathology

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813217.001).
  • [ISSN] 1362-4393
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Grover N, Chary G, Makhija P, Rout P: Extramedullary plasmacytoma of the nasal cavity: treatment perspective in a developing nation. Ear Nose Throat J; 2006 Jul;85(7):434-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary plasmacytoma of the nasal cavity: treatment perspective in a developing nation.
  • Extramedullary plasmacytomas are uncommon tumors, with a worldwide annual incidence of 3 per 100,000 population.
  • They account for 1% of all tumors of the head and neck and 4% of all nonepithelial tumors of the nasal tract.
  • We discuss the feasibility of surgery in such a circumstance, and we describe our surgical treatment of a case of extramedullary plasmacytoma in an elderly woman who presented to our hospital in India.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / surgery. Plasmacytoma / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909813.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Rehak S, Maisnar V, Malek V, Cesak T, Ryska P, Bartos M, Talab R: Diagnosis and surgical therapy of plasma cell neoplasia of the spine. Neoplasma; 2009;56(1):84-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and surgical therapy of plasma cell neoplasia of the spine.
  • Presented is a retrospective analysis of 27 patients with plasma cell neoplasms of the spine treated by surgery.
  • Multiple myeloma was confirmed in 22 (81%) and solitary plasmacytoma in 5 patients (19%), assessed at the time of surgery.
  • Nineteen patients (70%) with the preliminary diagnosis of malignancy of unknown etiology were admitted for surgery.
  • Thirteen patients (48%) were bedridden due to tumor spinal cord compression, on average for 7 days before undergoing surgery.
  • Key words: plasma cell neoplasia, spinal cord compression, late diagnosis, outcome.
  • [MeSH-major] Neoplasms, Plasma Cell / diagnosis. Neoplasms, Plasma Cell / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152251.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


69. Haegelen C, Riffaud L, Bernard M, Carsin-Nicol B, Morandi X: Dural plasmacytoma revealing multiple myeloma. Case report. J Neurosurg; 2006 Apr;104(4):608-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural plasmacytoma revealing multiple myeloma. Case report.
  • The authors describe the case of a 72-year-old woman with dural plasmacytoma revealing an immunoglobulin (Ig) G-kappa multiple myeloma (MM).
  • A diagnosis of IgG-kappa MM was based on microscopic examination and immunohistochemical analysis of the dural plasmacytoma as well as on signs of systemic myeloma after surgery.
  • The patient died 3 years after the first symptoms of MM despite systemic chemotherapy and no recurrence of the dural plasmacytoma.
  • Nevertheless, this pathological entity should be differentiated from solitary dural plasmacytoma (SDP) because the prognosis is radically different.
  • Progression seems to be correlated with systemic disease in contrast to the long-term survival associated with SDP.
  • [MeSH-major] Dura Mater / surgery. Meningeal Neoplasms / surgery. Multiple Myeloma / surgery. Plasmacytoma / surgery
  • [MeSH-minor] Aged. Biopsy. Bone Marrow / pathology. Craniotomy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunoglobulin kappa-Chains / analysis. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / pathology. Neoplasms / pathology. Plasma Cells / pathology. Skull Neoplasms / diagnosis. Skull Neoplasms / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619666.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


70. Lee AR, Lee MS, Jung IS, Kim DY, Nham SS, Chung HW, Eom K: Imaging diagnosis--FDG-PET/CT of a canine splenic plasma cell tumor. Vet Radiol Ultrasound; 2010 Mar-Apr;51(2):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis--FDG-PET/CT of a canine splenic plasma cell tumor.
  • There was no evidence of metastasis or bone marrow involvement on PET/CT images.
  • The patient was diagnosed as splenic extramedullary plasmacytoma through immunohistopathologic study.
  • [MeSH-major] Dog Diseases / radionuclide imaging. Plasmacytoma / veterinary. Positron-Emission Tomography / veterinary. Splenic Neoplasms / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Fluorodeoxyglucose F18 / metabolism. Radiopharmaceuticals / metabolism. Splenectomy / veterinary. Tomography, X-Ray Computed / veterinary. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402398.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Danova NA, Robles-Emanuelli JC, Bjorling DE: Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs. Vet Surg; 2006 Jun;35(4):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs.
  • OBJECTIVE: To describe an anal approach for excision of primary rectal tumors in dogs and to report outcome.
  • ANIMALS: Dogs (n=23) with primary rectal tumors.
  • METHODS: Review of medical records (1990-2000) of dogs with primary rectal neoplasia excised surgically using an anal approach with rectal prolapse.
  • With dogs anesthetized, the rectum was prolapsed, stabilized with stay sutures during tumor excision with 1 cm margins to the level of the muscularis, then the rectal mucosa was sutured.
  • RESULTS: Each dog had only 1 tumor type (adenocarcinoma [8], solitary polyp [5], carcinoma [4], plasmacytoma [2], adenoma [1], leiomyoma [1], mucinous carcinoma [1], and papilloma [1]).
  • Mean tumor volume was 3.1 cm(3) (range 0.1-37.7 cm(3)).
  • The primary tumor was incompletely excised in 1 dog (4.3%), and local recurrence occurred 16 and 24 months after surgery in 2 dogs.
  • Mean postoperative disease-free interval for these 18 dogs was 36.8 months (range 5-84 months).
  • CONCLUSION: Surgical excision of tumors of the caudal rectum can be accomplished through the anus after rectal prolapse.
  • CLINICAL RELEVANCE: An anal approach facilitated by rectal prolapse should be considered as a viable option for the surgical treatment of selected cases of tumors of the caudal aspect of the rectum in dogs.
  • [MeSH-major] Anal Canal / surgery. Dog Diseases / surgery. Rectal Neoplasms / veterinary
  • [MeSH-minor] Adenocarcinoma / surgery. Adenocarcinoma / veterinary. Animals. Disease-Free Survival. Dogs. Female. Male. Polyps / surgery. Polyps / veterinary. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Treatment Outcome. Wisconsin / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756613.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J: [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases]. Ai Zheng; 2006 Apr;25(4):461-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
  • BACKGROUND & OBJECTIVE: Multiple myeloma (MM) is a heterogeneous disease of plasma cell tumor with poor prognosis.
  • This study was to explore the prognostic factors of MM in China, and find the most suitable clinical staging systems.
  • METHODS: Univariate and multivariate analyses were carried out on 18 clinical and laboratory indexes from 206 MM patients.
  • Univariate analysis identified 10 prognostic factors: age, the amount of bone marrow plasma cells, hemoglobin, platelet count, adjusted serum calcium, albumin, creatinine, beta2 microglobulin, C-reactive protein, and skeletal disease stage.
  • CONCLUSIONS: High level of C-reactive protein, high level of beta2 microglobulin, low level of albumin and old age are correlated to poor prognosis.
  • [MeSH-major] C-Reactive Protein / metabolism. Multiple Myeloma. beta 2-Microglobulin / blood

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613681.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Serum Albumin; 0 / beta 2-Microglobulin; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


73. Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL: Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol; 2005 Dec;29(12):1633-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIDS-associated aggressive B-cell lymphomas often have plasmacytoid features.
  • Plasma cell neoplasms in HIV patients were commonly described to have atypical morphology and an aggressive clinical course in the literature.
  • We reviewed 14 cases of neoplasms with marked plasmacytic differentiation in HIV-positive patients to determine their clinicopathologic features.
  • All patients had extramedullary and 11 of 13 had extranodal tumor at the initial presentation; 2 had distant marrow involvement.
  • The most commonly involved location was the oral cavity (6 of 13 cases), followed by bone and soft tissue (4 of 13), and the gastrointestinal tract (3 of 13).
  • The 14th patient who had a nodal disease with more undifferentiated morphology and expression of the HHV8 LNA protein was alive without disease at last follow-up (>72 months), probably representing a novel HHV8(+) lymphoma.
  • We conclude that most plasmacytic tumors in HIV-positive individuals are extramedullary, clinically aggressive EBV(+) tumors identical to plasmablastic lymphoma that does not have the clinical features of plasma cell myeloma.
  • [MeSH-major] HIV Seropositivity. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Multiple Myeloma / pathology


74. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J: Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia; 2007 Jan;21(1):158-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.
  • Multiple myeloma (MM) is a B-cell neoplasia caused by the proliferation of clonal plasma cells, primarily in the bone marrow (BM).
  • The role of the BM microenvironment in the pathogenesis of the disease has been demonstrated, especially for the survival and growth of the myeloma plasma cells.
  • Based on a series of 61 consecutive patients, we evaluated the ability of MSCs derived from myeloma patients to differentiate into adipocytes and osteocytes, inhibit T-cell functions, and support normal hematopoiesis.
  • As compared to normal MSCs, MSCs from MM patients exhibited normal phenotype, differentiation capacity and long-term hematopoietic support, but showed reduced efficiency to inhibit T-cell proliferation and produced abnormally high amounts of IL-6.
  • Importantly, these characteristics were observed in the absence of any detectable tumor plasma cell.
  • Chromosomal analysis revealed that MM patients MSCs were devoid of chromosomal clonal markers identified in plasma cells.
  • [MeSH-major] Mesenchymal Stromal Cells / pathology. Multiple Myeloma / pathology
  • [MeSH-minor] Adipocytes / pathology. Adult. Aged. Aged, 80 and over. Cell Communication. Cell Differentiation. Chromosome Aberrations. Hematopoiesis. Humans. Immunity, Cellular. Interleukin-6 / biosynthesis. Middle Aged. Osteoclasts / pathology. Plasma Cells / physiology. T-Lymphocytes / immunology. Up-Regulation


75. European Federation of Neurological Societies, Peripheral Nerve Society, Hadden RD, Nobile-Orazio E, Sommer C, Hahn A, Illa I, Morra E, Pollard J, Hughes RA, Bouche P, Cornblath D, Evers E, Koski CL, Léger JM, Van den Bergh P, van Doorn P, van Schaik IN: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol; 2006 Aug;13(8):809-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
  • BACKGROUND: Paraprotein-associated neuropathies have heterogeneous clinical, neurophysiological, neuropathological and haematological features.
  • Objectives. To prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein (paraproteinaemic demyelinating neuropathy, PDN).
  • (1) Patients with PDN should be investigated for a malignant plasma cell dyscrasia. (2) The paraprotein is more likely to be causing the neuropathy if the paraprotein is immunoglobulin (Ig)M, antibodies are present in serum or on biopsy, or the clinical phenotype is chronic distal sensory neuropathy. (3) Patients with IgM PDN usually have predominantly distal and sensory impairment, with prolonged distal motor latencies, and often anti-myelin associated glycoprotein antibodies. (4) IgM PDN sometimes responds to immune therapies.
  • Their potential benefit should be balanced against their possible side-effects and the usually slow disease progression. (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy, clinically, electrophysiologically, and in response to treatment. (6) For POEMS syndrome, local irradiation or resection of an isolated plasmacytoma, or melphalan with or without corticosteroids, should be considered, with haemato-oncology advice.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879290.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Morgan TK, Zhao S, Chang KL, Haddix TL, Domanay E, Cornbleet PJ, Arber DA, Natkunam Y: Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis. Am J Clin Pathol; 2006 Oct;126(4):545-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
  • Genome-wide expression studies using complementary DNA microarrays recently suggested a number of intriguing candidate genes for distinguishing plasma cell dyscrasias.
  • Our objective was to test select markers using immunohistochemical analysis and a tissue microarray from paraffin-embedded bone marrow core biopsy specimens obtained from 8 patients with monoclonal gammopathy of undetermined significance, 17 with plasmacytoma, 160 with multiple myeloma, and 15 with plasma cell leukemia (PCL).
  • PCL showed significantly less immunostaining for CD27 (P < .01) and p27 (P < .05) compared with plasmacytoma and multiple myeloma.
  • Low CD27 expression also was associated with plasmacytoma progression to multiple myeloma (P <.05).
  • Our results support the hypothesis that low CD27 expression correlates with high-risk disease, including primary PCL and decreased progression-free survival in solitary plasmacytoma.
  • [MeSH-major] Antigens, CD27 / metabolism. Leukemia, Plasma Cell / metabolism. Monoclonal Gammopathy of Undetermined Significance / metabolism. Multiple Myeloma / metabolism. Plasma Cells / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. Bone Marrow / metabolism. Bone Marrow / pathology. Disease Progression. Humans. Immunohistochemistry. Immunophenotyping. Single-Blind Method. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938662.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Sahin F, Saydam G, Ertan Y, Calli C, Dönmez A, Tombuloglu M: Dural plasmacytoma mimicking meningioma in a patient with multiple myeloma. J Clin Neurosci; 2006 Feb;13(2):259-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural plasmacytoma mimicking meningioma in a patient with multiple myeloma.
  • Apart from calvarial infiltration, intracranial involvement in multiple myeloma is uncommon.
  • The differential diagnosis of a dural plasmacytoma includes meningioma, which has a similar MRI appearance, metastasis, lymphoma and sarcoma of the dura mater.
  • We present a patient with multiple myeloma presenting with an intracerebral mass mimicking a meningioma on MRI.
  • Multiple myeloma had been diagnosed seven years previously.
  • The patient presented with headache and speech disturbance 12 months after autologous peripheral stem cell transplantation for recurrence of multiple myeloma.
  • Histopathological examination of the mass after excision showed multiple myeloma immunopositive for IgG, kappa light chain and CD38.
  • Plasmacytoma should be considered in the differential diagnosis of a solitary dural mass, particularly in a patient with multiple myeloma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Meningioma / diagnosis. Multiple Myeloma / complications. Plasmacytoma / diagnosis
  • [MeSH-minor] Antigens, CD38 / metabolism. Diagnosis, Differential. Dura Mater / pathology. Female. Humans. Immunoglobulin G / metabolism. Magnetic Resonance Imaging. Middle Aged. Speech Disorders / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459088.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Immunoglobulin G; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


78. Ria R, Di Ianni M, Sportoletti P, Cimminiello M, Marcomigni L, Tabilio A: Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. Leuk Lymphoma; 2006 Mar;47(3):549-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis.
  • In this case, originally reported as primary eyelid plasmacytoma, the tumor recurred on the same eyelid within 2 years of surgery.
  • No plasma cell infiltration was observed at bone marrow biopsy.
  • Histology and immunohistochemistry confirmed plasma cell infiltration.
  • Tumor cell clonality was determined by immunohistological staining; cells were positive for kappa light chain like the first eyelid tumor.
  • Twenty months later, biopsy of one enlarged right cervical lymph node showed massive diffuse infiltration of atypical plasma cells (CD20(-), CD79a(+), CD138(+), MUM1/IRF4(+)).
  • No plasma cell infiltration was observed at bone marrow biopsy.
  • As this case might be a particularly slow-progressing extra-medullary plasmacytoma, this study recommends closely monitored follow-ups so that the aggressive form can be treated in time.
  • [MeSH-major] Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Plasmacytoma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396779.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. El Abdi B, Arkha Y, Jroundi L, Mouhsine A, Chami I, Boujida N, Baccadi M: [What is your diagnosis? Frontal solitary plasmacytoma]. J Radiol; 2006 Jul-Aug;87(7-8):981-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What is your diagnosis? Frontal solitary plasmacytoma].
  • [Transliterated title] Quel est votre diagnostic? Plasmocytome solitaire frontal.
  • [MeSH-major] Frontal Bone / pathology. Plasmacytoma / diagnosis. Skull Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16888594.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


80. Wang YD, Hu Y, Huang J, Zhang L, Sun CY: Antitumor effect of anti-brain derived neurotrophic factor monoclonal antibody in human multiple myeloma xenograft animal model. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):1069-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effect of anti-brain derived neurotrophic factor monoclonal antibody in human multiple myeloma xenograft animal model.
  • This study was aimed to further explore whether brain derived neurotrophic factor (BDNF) pathway is a potential therapeutic target in multiple myeloma (MM) and whether anti-BDNF monoclonal antibody can prevent the development of this disease.
  • The in vivo antitumor effect of anti-BDNF monoclonal antibody (McAb) on a human myeloma xenograft animal model was evaluated.
  • The model of xenograft tumors was established in the nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice by subcutaneous injection of human myeloma cell line RPMI8226.
  • The antibodies were injected intraperitoneally at a dose of 20 microg/mouse at day 1, 2, 3 after inoculation or at a dose of 100 microg/mouse once a week after tumors were detected.
  • The microvascular densities in tumors were analyzed by immunohistochemistry study.
  • The results showed that multiple injections of anti-BDNF McAb reduced the tumor size, decreased the microvascular density and significantly prolonged tumor-free time and survival time.
  • It is concluded that anti-BDNF monoclonal antibody can inhibit cell growth and angiogenesis in subcutaneous plasmacytoma.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928597.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Brain-Derived Neurotrophic Factor
  •  go-up   go-down


81. Miltenyi Z, Toth J, Gonda A, Tar I, Remenyik E, Illes A: Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. Pathol Oncol Res; 2009 Sep;15(3):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris.
  • Castleman disease is a rare lymphoproliferative disorder.
  • The clinical signs and symptoms of the disease are primarily mediated by cytokines, especially interleukin-6.
  • We presented the case of a young female.
  • Histological examination and direct and indirect immunofluorescence confirmed the diagnosis of pemphigus.
  • Search for neoplasm revealed a retroperitoneal Castleman tumour sized 15 x 6 x 5 cm in the abdominal MRI.
  • The tumour was a bleeder, so the removal was partial.
  • Histological examination showed hyalin hypervascular Castleman disease.
  • Considering her young, fertile age and the multicentric Castleman disease, non-cytostatic immunomodulatory therapy was started including steroid, cyclosporine-A and thalidomide treatment.
  • The control abdominal CT showed a small residual tumour on the bladder.
  • The residual tumour was removed in repeated surgery.
  • At this time the histological examination showed transient type tumour between plasma cell and vascular variant.
  • 4 years after the onset of the disease. (18)FDG PET/CT examination showed low metabolic active mass in the right iliacal region, but our patient had no symptoms or complaints.
  • She is on 200 mg thalidomide a day and no tumour progression can be seen.
  • Castleman disease can be successfully treated with non-cytostatic immunomodulatory therapy.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Cyclosporine / therapeutic use. Female. Humans. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Retroperitoneal Neoplasms / complications. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / pathology. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Pemphigus.
  • Genetic Alliance. consumer health - Pemphigus vulgaris.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2005 Apr;129(1):3-17 [15801951.001]
  • [Cites] N Engl J Med. 1990 Dec 20;323(25):1729-35 [2247105.001]
  • [Cites] Br J Haematol. 2006 Sep;134(5):544-5 [16856889.001]
  • [Cites] Am J Hematol. 2006 Apr;81(4):303-4 [16550518.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):393-400 [10459112.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Am J Hematol. 2003 May;73(1):48-53 [12701121.001]
  • [Cites] Neth J Med. 2002 Dec;60(11):444-7 [12685494.001]
  • [Cites] Arch Gynecol Obstet. 2004 Jan;269(2):156-8 [14648185.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):682-4 [15357753.001]
  • [Cites] Curr Opin Hematol. 2007 Jul;14 (4):354-9 [17534161.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1143-51 [14674890.001]
  • [Cites] J Investig Dermatol Symp Proc. 2004 Jan;9(1):29-33 [14870982.001]
  • [Cites] Acta Oncol. 2004;43(8):698-704 [15764213.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2627-32 [15998837.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1881-3 [17786732.001]
  • [Cites] N Engl J Med. 1954 Jan 7;250(1):26-30 [13111435.001]
  • (PMID = 19067241.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


82. Kuliszkiewicz-Janus M, Zimny A, Sokolska V, Saşiadek M, Kuliczkowski K: Immunoglobulin D myeloma--problems with diagnosing and staging (own experience and literature review). Leuk Lymphoma; 2005 Jul;46(7):1029-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin D myeloma--problems with diagnosing and staging (own experience and literature review).
  • Immunoglobulin D (IgD) myeloma is a rare disease accounting for about 2% of all myelomas.
  • The distinctive features are the predominant occurrence in males and young patients, short survival time, uncertain appearance of M-component in serum electrophoresis, predominance of lambda light chains, frequent renal impairment, hypercalcemia and amyloidosis.
  • Five of them were diagnosed as IgD multiple myeloma (IgD MM), 1 as non-secretory IgD myeloma and 1 as solitary bone IgD plasmocytoma that evolved to an IgD MM.
  • We report diagnostic problems with IgD myeloma in our patients, with special emphasis on non-specific rheumatoidal and neurological symptoms in 1 case.
  • There was a very good correlation of the Japanese classification with the severity of the disease and the risk of death.
  • In conclusion, the initial symptoms of IgD myeloma can be very misleading.
  • Wide differential diagnosis, including autoimmunological disorders of the connective tissue, is necessary.
  • The new Japanese risk grouping seems to be of greater prognostic significance for IgD myeloma than the Durie and Salmon staging system.
  • [MeSH-major] Immunoglobulin D / analysis. Multiple Myeloma / diagnosis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019554.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


83. Shaheen SP, Talwalkar SS, Medeiros LJ: Multiple myeloma and immunosecretory disorders: an update. Adv Anat Pathol; 2008 Jul;15(4):196-210
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma and immunosecretory disorders: an update.
  • These disorders include multiple myeloma (MM) and its variants, plasmacytoma, Waldenstrom macroglobulinemia, monoclonal gammopathy of undetermined significance, and monoclonal Ig deposition diseases, the latter including primary amyloidosis and nonamyloidotic types.
  • These disorders are histologically composed of plasma cells, or plasmacytoid cells which produce Ig that is synthesized and usually secreted and can be deposited in some diseases.
  • Immunosecretory disorders have been classified in multiple schemes, mostly morphologic, to such a degree that the classification of these entities has become a challenge to pathologists.
  • The World Health Organization classification in 2001 was helpful because it provided specific clinicopathologic criteria for diagnosis.
  • However, terms such as "progressive" disease were not well defined.
  • In 2003, the International Myeloma Group defined MM as a disease with related organ and tissue injury, serving to better explain progressive in terms of deterioration of organ (renal, bone, and bone marrow) function over time.
  • Therefore, modern classification of immunosecretory diseases is based on integration of clinical, morphologic, laboratory, radiographic, and biologic (including molecular) parameters, which we review here.
  • [MeSH-major] Multiple Myeloma / classification. Multiple Myeloma / immunology
  • [MeSH-minor] Humans. Immunoglobulin G / metabolism. Paraproteinemias / classification. Paraproteinemias / immunology. Paraproteinemias / pathology. Plasma Cells / immunology. Plasma Cells / pathology. Plasmacytoma / classification. Plasmacytoma / immunology. Plasmacytoma / pathology. Waldenstrom Macroglobulinemia / classification. Waldenstrom Macroglobulinemia / immunology. Waldenstrom Macroglobulinemia / pathology. World Health Organization

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580096.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G
  • [Number-of-references] 68
  •  go-up   go-down


84. Pantelidou D, Tsatalas C, Margaritis D, Karayiannakis AJ, Kaloutsi V, Spanoudakis E, Katsilieris I, Chatzipaschalis E, Sivridis E, Bourikas G: Extramedullary plasmacytoma: report of two cases with uncommon presentation. Ann Hematol; 2005 Mar;84(3):188-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary plasmacytoma: report of two cases with uncommon presentation.
  • Lymph node infiltration by monoclonal plasma cells can occur either in aggressive forms of myeloma or may represent regional extension of extramedullary plasmacytomas, whereas lymph node plasmacytoma presenting as a solitary extramedullary plasmacytoma is very unusual.
  • We report two cases of lymph node plasmacytomas without systemic disease diagnosed after surgical excision.
  • Clinical remission was achieved after local radiotherapy although one patient relapsed with multifocal extramedullary plasmacytomas 20 months after radiotherapy.
  • [MeSH-major] Plasmacytoma / pathology
  • [MeSH-minor] Abdominal Neoplasms / pathology. Aged. Humans. Male. Middle Aged. Neoplasm Invasiveness. Plasma Cells / pathology. Retroperitoneal Neoplasms / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15042315.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Nakanishi K, Kashiwagi N, Hamada K, Yagi T, Tomita Y: Solitary plasmacytoma of the sternum detected incidentally by MR imaging of the cervical spine. Magn Reson Med Sci; 2010;9(4):227-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of the sternum detected incidentally by MR imaging of the cervical spine.
  • We incidentally detected a case of solitary plasmacytoma of the sternum by magnetic resonance (MR) imaging of the cervical spine.
  • At detection, the patient had no symptoms, the lesion was localized in the bone marrow of the sternum, and there were no findings of bone destruction.
  • The lesion showed high contrast on diffusion-weighted images, gradually enlarged over 3 years, and was confirmed as a solitary plasmacytoma at open biopsy 3 years after detection.
  • [MeSH-major] Cervical Vertebrae. Diffusion Magnetic Resonance Imaging / methods. Incidental Findings. Plasmacytoma / pathology. Sternum / pathology. Thoracic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187692.001).
  • [ISSN] 1880-2206
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Wei JY, Tong HY, Zhu WF, Liu H, Zhang FJ, Yu WJ, Jin J: Bortezomib in treatment of extramedullary plasmacytoma of the pancreas. Hepatobiliary Pancreat Dis Int; 2009 Jun;8(3):329-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
  • BACKGROUND: Extramedullary pancreatic plasmacytoma treated with bortezomib is rarely reported.
  • The diagnosis of extramedullary plasmacytoma (EMP) was made.
  • RESULTS: The data demonstrated that the diagnosis was EMP of the pancreas.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Boronic Acids / administration & dosage. Dexamethasone / administration & dosage. Pancreatic Neoplasms / drug therapy. Plasmacytoma / drug therapy. Pyrazines / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502179.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Boronic Acids; 0 / Pyrazines; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; VAD regimen
  •  go-up   go-down


87. D'Costa K, Emslie D, Metcalf D, Smyth GK, Karnowski A, Kallies A, Nutt SL, Corcoran LM: Blimp1 is limiting for transformation in a mouse plasmacytoma model. Blood; 2009 Jun 4;113(23):5911-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blimp1 is limiting for transformation in a mouse plasmacytoma model.
  • Multiple myeloma (MM) and plasmacytomas are cancers of antibody-secreting cells (ASCs).
  • In contrast, some diffuse large B-cell lymphomas (DLBCLs) lose PRDM1 expression, suggesting that PRDM1 may act as a tumor suppressor in DLBCL.
  • We have used a plasmacytoma-prone transgenic mouse model to study the effect of Blimp1 loss on plasmacytoma prevalence, latency, and phenotype.
  • Two possible outcomes could be envisaged: loss of Blimp1 might decrease plasmacytoma prevalence, through reduction of plasma cells, and so the number of susceptible transformation targets.
  • Our results support the latter scenario, showing that decreasing Blimp1 dosage does not change plasma cell number in nontransgenic mice in vivo, but it significantly reduces plasmacytoma prevalence in transgenic mice.
  • Loss of functional Blimp1 completely prevents plasmacytoma formation in this tumor model.
  • These observations suggest that Blimp1 is limiting for plasma cell transformation and thus has potential as a target for new therapies to combat MM.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Plasmacytoma / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Alleles. Animals. Disease Models, Animal. Female. Genotype. Male. Mice. Mice, Transgenic. Phenotype

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329782.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prdm1 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


88. O'Sullivan P, Müller NL: Pulmonary and nodal multiple myeloma mimicking lymphoma. Br J Radiol; 2006 Jul;79(943):e25-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary and nodal multiple myeloma mimicking lymphoma.
  • Multiple myeloma is a haematological malignancy characterized by the occurrence of plasma cell tumours within the bone marrow.
  • In advanced multiple myeloma, metastatic deposits outside the bone marrow (extramedullary) are rare.
  • Parenchymal pulmonary plasmacytoma is exceptionally rare.
  • 6 months post-transplantation developing nodal and hilar pulmonary multiple myeloma, the radiological appearances mimicking lymphoma.
  • [MeSH-major] Lung Neoplasms / radiography. Multiple Myeloma / radiography
  • [MeSH-minor] Bone Marrow Transplantation. Diagnosis, Differential. Humans. Lymphatic Metastasis / radiography. Lymphoproliferative Disorders / radiography. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Solitary Pulmonary Nodule / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823050.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Assier E, Boissier MC, Dayer JM: Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine; 2010 Dec;77(6):532-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interleukin-6 (IL-6) was identified based on extensive research conducted simultaneously on a variety of topics ranging from hepatocyte production of acute-phase proteins to plasmacytoma growth.
  • IL-6 is a cytokine produced by a broad array of cell types and can exert its effects on virtually all cells.
  • IL-6 can induce cell signaling not only via the classic pathway involving the transmembrane receptor IL-6Rα (restricted cellular expression) associated with gp130 (ubiquitous and responsible for signal transmission), but also via the soluble receptor IL-6Rα, which binds to IL-6 and induces a signal mediated by the ubiquitous gp130 molecule (transsignaling).
  • Tocilizumab is now indicated for the treatment of adults with RA who have failed at least one synthetic disease-modifying antirheumatic drug or TNFα antagonist.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antirheumatic Agents / immunology. Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Arthritis, Rheumatoid / immunology. Arthritis, Rheumatoid / metabolism. Cytokine Receptor gp130 / immunology. Cytokine Receptor gp130 / metabolism. Disease Models, Animal. Humans. Mice. Signal Transduction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20869898.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Interleukin-6; 0 / Interleukin-6 Receptor alpha Subunit; 0 / tocilizumab; 133483-10-0 / Cytokine Receptor gp130
  •  go-up   go-down


90. Bień S, Kobiorska-Nowak J: [Plasmocytoma in the nasal cavity and paranasal sinuses]. Otolaryngol Pol; 2009 May-Jun;63(3):287-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasmocytoma in the nasal cavity and paranasal sinuses].
  • INTRODUCTION: Plasma cell myeloma is a monoclonal neoplastic growth of plasmocytes--classified to a large group of B cell lymphomas.
  • In the majority of cases plasma cell myeloma manifest as a generalized neoplastic disease localized in the bones.
  • The most common localization of extramedullary plasmocytoma is a mucosa of the nasal cavity and paranasal sinuses.
  • The rest of myelomas within the nose and sinuses are in fact only one of mulitiple focuses, within a bone frame of the nose and sinuses.
  • MATERIAL: Case reports of three cases of plasma cell myeloma localised within the nose and paranasal sinuses; diagnosed and treated in Holy Cross Cancer Center- Kielce, Poland, from 2001 to 2008.
  • CASES PRESENTATION: Case I-- Male 49 years old--Extramedullary plasmocytoma localized in mucosa of the floor of nasal cavity.
  • Alive 57 months with symptoms of the disease.
  • Case II--Male 42 years old--Multiple myeloma with one of focuses in anterior wall of maxillary sinus.
  • Died due to the primary disease in 2 months.
  • Case III--Male 29 years old--Multiple myeloma with one of the focuses in posterior wall of maxillary sinus.
  • (1) Plasma cell myelomas in the nose and paranasal sinuses region are a rare tumors.
  • They may manifest as an isolated form of plasmocytoma, or a generalized disease as a one of focuses in the bone frame of the nose and sinuses or one of the focuses outside the bone. (2) The complex diagnosis and treatment of plasma cell myelomas require a multispecialistic approach, and should be conducted in oncological centers. (3) The ceases presented confirm, that a generalized myelomas usually have a bad prognosis.
  • In isolated form of plasmocytoma the long remissions or cure may be expected.
  • [MeSH-major] Multiple Myeloma / radiotherapy. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy. Plasmacytoma / therapy

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886539.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


91. Gouveris H, Hansen T, Franke K: Solitary extramedullary plasmacytoma and granulomatous sialadenitis of the parotid gland preceding a B-cell non-Hodgkin's lymphoma. Mund Kiefer Gesichtschir; 2006 Mar;10(2):122-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary extramedullary plasmacytoma and granulomatous sialadenitis of the parotid gland preceding a B-cell non-Hodgkin's lymphoma.
  • Ultrasonographically guided fine-needle biopsy could not provide any definitive diagnosis.
  • After partial parotidectomy with complete tumor removal the histologic exam showed an extramedullary plasmacytoma with concurrent non-necrotizing granulomatous sialadenitis of the parotid gland.
  • Complete systemic work-up excluded multiple myeloma, leukemia, lymphoma and sarcoidosis.
  • Six months after surgery an aggressive B-cell non-Hodgkin's lymphoma was diagnosed.
  • [MeSH-major] Granuloma / diagnosis. Lymphoma, B-Cell / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Parotid Neoplasms / diagnosis. Parotitis / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow / pathology. CREST Syndrome / diagnosis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Follow-Up Studies. Humans. Male. Parotid Gland / pathology. Parotid Gland / radiation effects. Parotid Gland / surgery. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Sialadenitis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):111-6 [9894461.001]
  • [Cites] South Med J. 1998 May;91(5):493-5 [9598864.001]
  • [Cites] J Laryngol Otol. 1998 Feb;112(2):179-81 [9578882.001]
  • [Cites] J Clin Pathol. 1996 Mar;49(3):208-12 [8675730.001]
  • [Cites] Br J Dermatol. 2001 Jan;144(1):182-5 [11167703.001]
  • [Cites] Rheumatol Int. 1999;18(5-6):177-80 [10399792.001]
  • [Cites] Histopathology. 1987 Feb;11(2):131-44 [3570176.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):365-8 [11860317.001]
  • [Cites] J Laryngol Otol. 1991 Aug;105(8):687-92 [1919333.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1986 Mar;65(3):127-9 [3713388.001]
  • [Cites] Laryngoscope. 1980 Mar;90(3):486-93 [7359969.001]
  • (PMID = 16489463.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


92. Lu HS, Xu YF, Gan MF: Primary gastric plasmacytoma associated with Helicobacter pylori infection: a report of two cases with different prognosis. Int J Hematol; 2010 Jul;92(1):174-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric plasmacytoma associated with Helicobacter pylori infection: a report of two cases with different prognosis.
  • We describe two cases of primary gastric plasmacytoma (GP) associated with Helicobacter pylori infection.
  • Case 1 was that of a 58-year-old man with epigastric pain. H. pylori was eradicated before surgical resection was performed, and after the therapy, the tumor size was reduced.
  • A postoperative pathological examination revealed that the tumor was in early stage and histological grade was grade 1.
  • Case 2 was that of a 70-year-old woman with a history of melena. H. pylori eradication was not presented preoperatively.
  • The resected specimen showed the tumor was in advanced stage and histological grade 3.
  • In our opinion, GP cannot be eradicated with H. pylori eradication, but disease progression can be effectively controlled to a certain extent.
  • The prognosis of this disease is relatively fair when treated at an early stage.
  • In addition to the treatment, the difference in prognosis could be associated with age, the stage of the tumor, and histological grade.
  • [MeSH-major] Helicobacter Infections / complications. Plasmacytoma / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 2004 Oct;83(10):666 [15449033.001]
  • [Cites] J Clin Gastroenterol. 2005 Jan;39(1):56-7 [15599212.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2005 Jun;102(6):687-92 [15981625.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):150-3 [19047299.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1266-8 [10541102.001]
  • [Cites] Ann Hematol. 2003 Sep;82(9):589-92 [12898183.001]
  • [Cites] Acta Gastroenterol Latinoam. 1999;29(3):119-23 [10533659.001]
  • [Cites] World J Gastroenterol. 2008 Apr 21;14(15):2388-93 [18416467.001]
  • [Cites] Intern Med. 2003 Apr;42(4):370-2 [12729330.001]
  • [Cites] Gastroenterol Hepatol. 2008 Apr;31(4):217-20 [18405486.001]
  • [Cites] Br J Cancer. 1997;75(6):921-7 [9062417.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):344-7 [11773190.001]
  • [Cites] Leukemia. 2009 Jan;23(1):3-9 [18971951.001]
  • [Cites] Gastrointest Endosc. 2001 Mar;53(3):352-5 [11231401.001]
  • [Cites] J Gastroenterol. 2002;37(5):398-401 [12051542.001]
  • (PMID = 20461561.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Turk HM, Komurcu S, Ozet A, Kuzhan O, Günhan O: An unusual presentation of extramedullary plasmacytoma in testis and review of the literature. Med Oncol; 2010 Dec;27(4):1378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of extramedullary plasmacytoma in testis and review of the literature.
  • Extramedullary plasmacytoma is a rare plasma cell neoplasm, and it is extremely uncommon in the testicles.
  • We report a 73-year-old man with multiple myeloma presented with testicular plasmacytoma.
  • Pathologic examination of the orchiectomy specimen showed plasmocytoma with kappa expression.
  • Multiple lytic bone lesions were seen in bone survey scans, serum immunoelectrophoresis and bone marrow aspiration aided to the diagnosis of multiple myeloma.
  • He succumbed to disease after 8 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / diagnosis. Orchiectomy. Plasmacytoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Prognosis. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):692-701 [12062614.001]
  • [Cites] Arch Pathol Lab Med. 1991 Jun;115(6):629-32 [1903919.001]
  • [Cites] JAMA. 1992 Nov 25;268(20):2946-51 [1433713.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):717-26 [15009059.001]
  • [Cites] Urology. 1989 Jul;34(1):51-4 [2665287.001]
  • [Cites] Crit Rev Oncol Hematol. 1988;8(2):93-152 [3046767.001]
  • [Cites] Br J Urol. 1964 Jun;36:SUPPL:85-94 [14184714.001]
  • [Cites] Radiother Oncol. 1990 Apr;17(4):293-303 [2343147.001]
  • [Cites] Am J Hematol. 2002 Oct;71(2):98-104 [12353308.001]
  • [Cites] Cancer. 1970 May;25(5):1193-203 [5443739.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):113-20 [11316553.001]
  • [Cites] AMA Arch Pathol. 1952 Mar;53(3):262-72 [14902231.001]
  • [Cites] Urology. 1978 Jan;11(1):90-2 [622772.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):128-33 [7819027.001]
  • (PMID = 20035386.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Martin P, Garcia-Cosio M, Santon A, Bellas C: Aberrant gene promoter methylation in plasma cell dyscrasias. Exp Mol Pathol; 2008 Jun;84(3):256-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant gene promoter methylation in plasma cell dyscrasias.
  • The aberrant methylation of promoter CpG island is known to be a major inactivation mechanism of tumour-related genes.
  • To determine the clinicopathological significance of gene promoter methylation in monoclonal gammopathies, we analysed the methylation status of 6 tumour suppressor genes and their association with loss of gene function.
  • Methylation status of the genes p14, p15, p16, hMLH1, MGMT, and DAPK was determined by methylation-specific PCR in 52 cases: 30 MM, 13 MGUS, and 9 plasmacytomas, comparing them with their protein expression by immunohistochemistry, and association between methylation status, protein expression, and clinical characteristics was assessed.
  • In plasmacytomas samples we found methylation of p16 in 55%, p15 in 22%, MGMT in 67% and DAPK in 44%.
  • hMLH1 was unmethylated in all cases of MGUS and plasmacytomas.
  • Our study demonstrates that methylation-mediated silencing is a frequent event in monoclonal gammopathies: 83% of MM, 46% of MGUS and 77% of plasmacytomas have at least one gene methylated, affecting different molecular pathways involved in cell cycle, DNA repair and apoptosis.
  • This high prevalence of aberrant promoter hypermethylation suggests that monoclonal gammopathies carry a CpG island methylator phenotype, therefore the development of new DNA demethylation agents may be a potential therapeutic use in this disease.
  • [MeSH-major] DNA Methylation. Leukemia, Plasma Cell / metabolism. Paraproteinemias / metabolism. Plasma Cells / metabolism. Plasmacytoma / metabolism. Promoter Regions, Genetic. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Multiple Myeloma / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410922.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins
  •  go-up   go-down


95. László I, Gábor V, Zsolt B, László T, József J: Synchronous myeloproliferative and inflammatory disease of the nasal cavity and paranasal sinuses: an interesting differential diagnostic problem. Rhinology; 2009 Sep;47(3):323-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous myeloproliferative and inflammatory disease of the nasal cavity and paranasal sinuses: an interesting differential diagnostic problem.
  • The authors present a case of synchronous manifestation of a myeloproliferative--extramedullary plasmocytoma--and a chronic inflammatory disease of the nose and the paranasal sinuses.
  • They emphasise the importance of imaging techniques and immunohistochemistry in the differential diagnosis.
  • They discuss on the basis of published articles the new classification, clinical manifestations, diagnostic and therapeutical approaches of this tumour belonging to the group of monoclonal gammopathies, which originates from an abnormal proliferation of mature B-lymphocytes, and is a rarity in the literature even nowadays.
  • [MeSH-major] Myeloproliferative Disorders / diagnosis. Nose Diseases / diagnosis. Paranasal Sinus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Inflammation / pathology. Magnetic Resonance Imaging. Middle Aged. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Plasmacytoma / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839260.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


96. Kane S, Khurana A, Parulkar G, Shet T, Prabhash K, Nair R, Gujral S: Minimum diagnostic criteria for plasmablastic lymphoma of oral/sinonasal region encountered in a tertiary cancer hospital of a developing country. J Oral Pathol Med; 2009 Jan;38(1):138-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimum diagnostic criteria for plasmablastic lymphoma of oral/sinonasal region encountered in a tertiary cancer hospital of a developing country.
  • BACKGROUND: Haematolymphoid tumours other than plasmablastic lymphoma (PBL) may reveal plasmablastic differentiation with overlapping immunoreactivity causing diagnostic dilemma.
  • METHODS: Out of 98 total cases of primary non-Hodgkin's lymphoma and plasmacytoma of oral-sinonasal region recorded in our institute over 4 years, 39 cases showing varied plasmablastic differentiation were selected.
  • (1) predominant population of plasmablasts which are large monomorphic cells with high nuclear-cytoplasmic ratio, moderate amount of amphophilic cytoplasm and round nucleus with prominent central nucleolus, (2) high mitotic and/or apoptotic index and (3) absence of neoplastic plasma cells in the background.
  • EBER positivity confirmed the diagnosis in all the HIV-negative cases.
  • CONCLUSIONS: A triad of 'rapidly growing lesion with predilection for oral mucosa, classical plasmablastic morphology and limited immunohistochemical panel' can render a reliable diagnosis of PBL, irrespective of HIV and EBV status, especially in developing countries with limited resources.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Mouth Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Antinuclear / analysis. Antibodies, Monoclonal / analysis. Antigens, CD20 / analysis. Apoptosis. Cancer Care Facilities. Cell Nucleolus / pathology. Cell Nucleus / pathology. Cytoplasm / pathology. Developing Countries. Diagnosis, Differential. Epstein-Barr Virus Infections / diagnosis. Humans. India. Ki-67 Antigen / analysis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Mitosis. Plasma Cells / pathology. Plasmacytoma / diagnosis. Syndecan-1 / analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647219.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / VS38 monoclonal antibody
  •  go-up   go-down


97. Nasr Ben Ammar C, Ghorbel I, Kochbati L, Gargouri W, Touati S, Maalej M: [Solitary and extramedullary plasmocytoma in the head and neck region: five cases report]. Cancer Radiother; 2010 Dec;14(8):755-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary and extramedullary plasmocytoma in the head and neck region: five cases report].
  • [Transliterated title] Plasmocytome solitaire extramédullaire de la tête et du cou: à propos de cinq cas.
  • PURPOSE: To assess the outcome and the management of solitary extramedullary plasmocytoma in the head and neck region.
  • PATIENTS AND METHODS: From 1997 to 2008, five cases of solitary extramedullary plasmocytoma were treated in the department of radiotherapy at Salah-Azaiz Institute.
  • Three patients had a solitary plasmocytoma of the nasal fossa; the others were ethmoidal and submandibular node.
  • Multiple myeloma occurred in one patient 8 years after treatment.
  • Local control of extramedullary plasmocytoma in the head and neck region seems to be improved when the dose is at least 45 Gy.
  • Predictive parameters of unfavourable outcome and conversion of extramedullary plasmocytoma to multiple myeloma should be better defined.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Plasmacytoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease Progression. Ethmoid Bone / pathology. Ethmoid Bone / surgery. Female. Humans. Male. Maxillary Neoplasms / pathology. Maxillary Neoplasms / radiotherapy. Maxillary Neoplasms / surgery. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / radiotherapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local / radiotherapy. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Remission Induction. Skull Neoplasms / pathology. Skull Neoplasms / radiotherapy. Skull Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20673736.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


98. Ko S, Huang SY, Liu CY: Extramedullary plasmacytoma masquerading as Tolosa-Hunt syndrome: a case report. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary plasmacytoma masquerading as Tolosa-Hunt syndrome: a case report.
  • Painful ophthalmoplegia due to extramedullary plasmacytoma is a rare initial manifestation of multiple myeloma.
  • Imaging studies revealed a multilobulated tumour invading the left sphenoid bone and sphenoid sinus, later confirmed as a plasmacytoma at pathology.
  • Multiple myeloma was also diagnosed by bone marrow examination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otolaryngol Suppl. 1994;511:200-3 [8203229.001]
  • [Cites] Intern Med. 1999 Dec;38(12):988-90 [10628940.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1039-44; discussion 1044-5 [11846895.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Am J Ophthalmol. 1992 May 15;113(5):489-96 [1575221.001]
  • [Cites] Br J Haematol. 2006 Sep;134(5):451 [16787499.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):896-905 [17594697.001]
  • [Cites] Medicine (Baltimore). 2007 Sep;86(5):278-81 [17873757.001]
  • [Cites] Brain. 1987 Feb;110 ( Pt 1):197-211 [3801850.001]
  • [Cites] J Clin Oncol. 1983 Apr;1(4):255-62 [6668499.001]
  • [Cites] J Fr Ophtalmol. 1995;18(12):771-6 [8745710.001]
  • [Cites] Br J Ophthalmol. 1998 Apr;82(4):458-9 [9640204.001]
  • [Cites] J Otolaryngol. 2001 Jun;30(3):184-6 [11771050.001]
  • [Cites] Medicine (Baltimore). 1976 May;55(3):217-38 [1272069.001]
  • [Cites] Br Med J. 1955 Mar 19;1(4915):708 [14351755.001]
  • [Cites] J Neuroophthalmol. 2003 Dec;23(4):268-71 [14663307.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):1 [14675400.001]
  • [Cites] Curr Pain Headache Rep. 2004 Aug;8(4):321-9 [15228894.001]
  • [Cites] Cephalalgia. 2004;24 Suppl 2:8-15 [15595989.001]
  • [Cites] South Med J. 1978 Sep;71(9):1171-4 [684509.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Cancer. 1978 Nov;42(5):2399-406 [719616.001]
  • [Cites] Rinsho Ketsueki. 1994 Aug;35(8):792-7 [7933568.001]
  • [Cites] J Neuroophthalmol. 2000 Dec;20(4):242-5 [11130748.001]
  • (PMID = 21686622.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029032
  •  go-up   go-down


99. Shao H, Xi L, Raffeld M, Pittaluga S, Dunleavy K, Wilson WH, Spector N, Milito C, Morais JC, Jaffe ES: Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression. Am J Surg Pathol; 2010 Oct;34(10):1425-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression.
  • Plasmacytomas expressing immunoglobulin A are rare and not well characterized.
  • In this study, 9 cases of IgA-positive plasmacytoma presenting in lymph node and 3 in extranodal sites were analyzed by morphology, immunohistochemistry, and polymerase chain reaction examination of immunoglobulin heavy and κ light chain genes.
  • Laboratory features were correlated with clinical findings.
  • Six of the patients were younger than 30 years of age, 5 of whom had nodal disease.
  • About 67% (6 of 9) of the patients with nodal disease had evidence of immune system dysfunction, including human immunodeficiency virus infection, T-cell deficiency, autoantibodies, arthritis, Sjögren syndrome, and decreased B cells.
  • All patients had an indolent clinical course without progression to plasma cell myeloma.
  • Histologically, nodal IgA plasmacytomas showed an interfollicular or diffuse pattern of plasma cell infiltration.
  • The plasma cells were generally of mature Marschalko type with little or mild pleomorphism and exclusive expression of monotypic IgA.
  • Our results suggest that IgA plasmacytomas may represent a distinct form of extramedullary plasmacytoma characterized by younger age at presentation, frequent lymph node involvement, and low risk of progression to plasma cell myeloma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):197-204 [20511165.001]
  • [Cites] Neoplasma. 1970;17(2):197-204 [4193284.001]
  • [Cites] Eur J Pediatr. 1978 Dec 1;129(4):239-57 [309818.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):541-4 [7137088.001]
  • [Cites] J Clin Oncol. 1983 Apr;1(4):255-62 [6668499.001]
  • [Cites] Cancer. 1985 Oct 15;56(8):2143-7 [3928137.001]
  • [Cites] Arch Pathol Lab Med. 1986 Feb;110(2):157-8 [3511882.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1475-85 [3102035.001]
  • [Cites] Am J Clin Pathol. 1987 Mar;87(3):342-55 [3825999.001]
  • [Cites] Histopathology. 1989 Jan;14(1):11-24 [2925176.001]
  • [Cites] Histopathology. 1989 Apr;14(4):333-46; discussion 429-32 [2737612.001]
  • [Cites] Clin Exp Immunol. 1990 Feb;79(2):170-4 [2311296.001]
  • [Cites] Histopathology. 1990 Aug;17(2):135-40 [2227838.001]
  • [Cites] Am J Med. 1990 Dec;89(6):816-8 [2252051.001]
  • [Cites] J Exp Med. 1992 Mar 1;175(3):671-82 [1371300.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):770-5 [1401205.001]
  • [Cites] Am J Hematol. 1993 Jul;43(3):237-9 [8352244.001]
  • [Cites] Hum Pathol. 1994 Dec;25(12):1269-75 [8001920.001]
  • [Cites] Am J Clin Pathol. 1996 Mar;105(3):268-76 [8602606.001]
  • [Cites] Int J Hematol. 1996 Jul;64(1):47-52 [8757967.001]
  • [Cites] Br J Cancer. 1997;75(6):921-7 [9062417.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Br J Ophthalmol. 2005 Mar;89(3):352-9 [15722318.001]
  • [Cites] J Neuroimmunol. 2005 Oct;167(1-2):120-30 [16099056.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1361-4 [15878199.001]
  • [Cites] Histopathology. 2006 Jan;48(2):162-73 [16405665.001]
  • [Cites] Leukemia. 2006 Jan;20(1):176-9 [16307010.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):176-81 [17210522.001]
  • [Cites] Med Oncol. 2007;24(4):445-8 [17917096.001]
  • [Cites] Histopathology. 2008 Mar;52(4):436-44 [18315596.001]
  • [Cites] Singapore Med J. 2008 Aug;49(8):e215-6 [18756337.001]
  • [Cites] J Clin Rheumatol. 2009 Sep;15(6):292-4 [19734735.001]
  • [Cites] Diagn Cytopathol. 2009 Dec;37(12):910-4 [19582804.001]
  • [Cites] J Pathol. 2000 Jan;190(1):47-54 [10640991.001]
  • [Cites] Haematologica. 2000 Jan;85(1):47-51 [10629591.001]
  • [Cites] Immunity. 2000 Oct;13(4):443-51 [11070163.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):119-26 [11190797.001]
  • [Cites] Curr Treat Options Oncol. 2002 Jun;3(3):255-9 [12057071.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):182-6 [12720133.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):e244-7 [19858382.001]
  • [Cites] Clin Rheumatol. 2010 Nov;29(11):1323-6 [20213125.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):717-26 [15009059.001]
  • (PMID = 20871216.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Immunoglobulin A; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  • [Other-IDs] NLM/ NIHMS229449; NLM/ PMC2947321
  •  go-up   go-down


100. Zazpe I, Caballero C, Cabada T, Guerrero D, Gallo-Ruiz A, Portillo E: Solitary thoracic intradural extramedullary plasmacytoma. Acta Neurochir (Wien); 2007;149(5):529-32; discussion 532
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary thoracic intradural extramedullary plasmacytoma.
  • The bodies of the vertebrae are common locations for plasma cell diseases such as multiple myeloma and solitary plasmacytoma.
  • Spinal cord compression due to pure intradural plasma cell infiltration is very rare.
  • The authors report a 25-year-old woman who developed a progressive difficulty in walking due to a solitary spinal dural plasmacytoma.
  • This is the first reported example in the English language literature of a purely intradural spinal plasmacytoma in a patient without other myelomatous lesions.
  • An entirely intradural solitary plasmacytoma has a relatively better prognosis.
  • [MeSH-major] Plasmacytoma / pathology. Plasmacytoma / radiography. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404683.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down






Advertisement